Building block for trifluoroalkylation and trifluoroalkylation method using same
A copper complex compound for trifluoroalkylation addresses the limitations of existing fluorine-18 labeling methods by enhancing the stability and cell penetration of radiopharmaceuticals, enabling efficient and scalable production of fluorine-18 labeled compounds.
Patent Information
- Application Number
- PCT/KR2024/006984
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-09
- Filing Date
- 2024-05-23
- Publication Date
- 2024-11-28
AI Technical Summary
Current methods for producing fluorine-18 labeled radiopharmaceuticals face limitations such as instability of precursors, complexity in synthesis, and time-consuming separation and purification processes, and existing building blocks like [18F]fluoroethyl and [18F]fluoropropylsulfonyl chloride have issues with stability and cell penetration.
Development of a copper complex compound for trifluoroalkylation that can be used as a building block for labeling fluorine-18, allowing for the substitution of a trifluoromethyl or trifluoroethyl group into ligands, enhancing in vivo stability and cell penetration.
The copper complex compound enables the production of radiopharmaceuticals with improved stability and cell penetration, facilitating efficient and scalable synthesis of fluorine-18 labeled compounds.
Smart Images

Figure KR2024006984_28112024_PF_FP_ABST
Abstract
Description
Building blocks for trifluoroalkylation and trifluoroalkylation methods using the same
[0001] The present invention relates to a building block that can be utilized for trifluoroalkylation in the production of a radioactive fluorine-18 labeled radiopharmaceutical for medical diagnosis, a method for producing the same, and a method for trifluoroalkylating a ligand using the same.
[0002]
[0003] Meanwhile, this application was supported by the following national research and development project.
[0004] [National Research and Development Project Supporting This Invention]
[0005] [Project ID] 1711191663
[0006] [Assignment Number] 2022R1F1A1072205
[0007] [Ministry Name] Ministry of Science and ICT
[0008] [Name of Project Management (Specialist) Institution] National Research Foundation of Korea
[0009] [Research Project Name] Basic Research
[0010] [Research Project Title] Development of a New CF2[18F]-Labeling Technology for Rapid and Accurate New Drug Evaluation
[0011] [Name of the project performing organization] Bundang Seoul National University Hospital
[0012] Research Period: June 1, 2022 - February 28, 2025
[0013]
[0014] [National Research and Development Project Supporting This Invention]
[0015] [Project ID] 1711179759
[0016] [Assignment Number] 2021R1A2C2003301
[0017] [Ministry Name] Ministry of Science and ICT
[0018] [Name of Project Management (Specialist) Institution] National Research Foundation of Korea
[0019] [Research Project Name] Mid-career Research
[0020] [Research Project Title] Development of pH- and temperature-sensitive nanocomposite-based nanocarriers that enhance the loading capacity, tumor selectivity, and retention of mitochondrial-targeting tumor therapeutic drugs.
[0021] [Name of the project performing organization] Bundang Seoul National University Hospital
[0022] Research Period: March 1, 2021 - February 8, 2026
[0023] Positron Emission Tomography (PET) is an imaging technique primarily used in nuclear medicine. It provides information on the diagnosis and therapeutic efficacy of diseases by noninvasively showing the distribution and activity of radiopharmaceuticals injected into the body. Fluorine-18 is the most widely used radioisotope in PET due to its suitable half-life of 110 minutes and its physical and chemical properties. There are two methods for producing fluorine-18-labeled radiopharmaceuticals. One method is to label a biologically active target compound with fluorine-18 in the final stage of the reaction (late-stage radiofluorination). The other method is to effectively introduce fluorine-18 into the target compound using a building block that has already been labeled with fluorine-18.
[0024] The final step of labeling with fluorine-18 has been used to overcome the limitations of fluorine-18 labeling reactions over the past decade. However, it still suffers from limitations such as precursor instability, synthetic complexity, and time-consuming separation and purification processes. Therefore, building block-based methods have been studied as an alternative to fluorine-18 labeling reactions due to their availability and ease of synthesis. Furthermore, the development of fluorine-18-labeled building blocks with high labeling yields, purity, and a simple method under appropriate conditions offers significant advantages in terms of scalability, as these building blocks can be incorporated into a variety of biologically active molecules.
[0025] Until recently, in the manufacture of radiopharmaceuticals, [ 18 [F] The building blocks used in the fluoroethyl group substitution reaction are [ 18 F]Fluoropropylsulfonyl chloride reagents are known. However, when using these reagents, -CH2[ 18 [F] is a flag, but this structure has the problem of low stability in the body and low cell penetration.
[0026] As a result of extensive efforts, the inventors of the present invention have found that in order to improve the stability and cell penetration of radiopharmaceuticals in the body, -CF2[ 18 The present invention was achieved by developing a building block capable of indicating the flag of [F] and a method for manufacturing the same.
[0027] One object of the present invention is to provide a building block that can be utilized for trifluoroalkylation and a method for producing the same.
[0028] Another object of the present invention is to provide a method for trifluoroalkylating a ligand using the above-described building block.
[0029] Another object of the present invention is to provide a method for producing -CF2[ through the above-described building block. 18[F] We aim to provide a radiopharmaceutical labeled with fluorine-18 by substituting the radioactive isotope.
[0030] However, the technical problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned can be clearly understood by those skilled in the art from the description below.
[0031] Hereinafter, various embodiments described herein will be described with reference to the drawings. In the following description, various specific details, such as specific configurations, compositions, and processes, are set forth to provide a thorough understanding of the present invention. However, certain embodiments may be practiced without one or more of these specific details, or in conjunction with other known methods and configurations. In other instances, well-known processes and manufacturing techniques have not been described in specific detail so as not to unnecessarily obscure the present invention. Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, configuration, composition, or characteristic described in connection with the embodiment is included in one or more embodiments of the present invention. Thus, the appearances of "in one embodiment" or "an embodiment" in various places throughout this specification do not necessarily refer to the same embodiment of the present invention. Additionally, the particular features, configurations, compositions, or characteristics may be combined in any suitable manner in one or more embodiments.
[0032]
[0033] The term "halogen" as used herein, unless otherwise stated, means fluorine, chlorine, bromine or iodine.
[0034] As used herein, the term "C1-C6 alkyl", unless otherwise stated, refers to a straight-chain or branched hydrocarbon residue having 1 to 6 carbon atoms. Examples thereof include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, t-butyl, n-pentyl, n-hexyl, and the like.
[0035] The term "C1-C6 alkoxy" as used herein means -O-alkyl, where alkyl is as disclosed above. Examples thereof include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, sec-butoxy, n-pentoxy, and the like. The alkoxy may be substituted or unsubstituted alkoxy.
[0036] The term "heterocycle" as used herein is understood to mean a partially unsaturated (heterocycloalkenyl) hydrocarbon ring having 3 to 15 carbon atoms in the form of a monocyclic, bicyclic, fused, bridged or spirocyclic ring.
[0037] The term "aryl" as used herein, unless otherwise stated, refers to a mono- or poly-cyclic carbocyclic ring system of 6 to 14 carbon atoms having one or more aromatic rings, fused or non-fused, examples of aryl include, but are not limited to, phenyl, naphthyl, tetrahydronaphthyl, indenyl, and andracenyl.
[0038] The term "heteroaryl" as used herein, unless otherwise stated, means a 5 to 14 membered monocyclic or bicyclic or higher aromatic group containing one or more heteroatoms selected from O, N and S, for example, 1 to 4 heteroatoms. Examples of monocyclic heteroaryls include, but are not limited to, thiazolyl, oxazolyl, thiophenyl, furanyl, pyrrolyl, imidazolyl, benzo[d]oxazolyl, isoxazolyl, oxazolopyridinyl, pyrazolyl, triazolyl, thiazolyl, benzo[d]thiazolyl, thiadiazolyl, tetrazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, quinolinyl, naphthoxazolyl and similar groups. Examples of bicyclic heteroaryls include, but are not limited to, indolyl, benzothiophenyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzthiazolyl, benzthiadiazolyl, benztriazolyl, quinolinyl, isoquinolinyl, purinyl, furopyridinyl, carbazolyl, dibenzofuranyl, dibenzothiophenyl, and similar groups.
[0039]
[0040] According to one embodiment of the present invention, the present invention relates to a building block composition for trifluoroalkylation comprising a copper complex compound represented by the following chemical formula 1.
[0041] [Chemical Formula 1]
[0042]
[0043] In the above chemical formula 1,
[0044] Cy1 to Cy4 are each independently a heteroaryl or heterocycloalkenyl ring having 4 to 8 atoms,
[0045] Cy5 and Cy6 are each independently a cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl or heterocycloalkenyl ring having 0 to 8 atoms, (wherein 0 atoms means no ring).
[0046] R 1 Inland R 6 are each independently hydrogen, halogen, nitro, C1~C6 alkyl group or C6~C 14 As an aryl group, it is a mono-substituent or a multi-substituent that is the same or different,
[0047] X 1 may be a halogen other than a fluoro group.
[0048] In the present invention, the copper complex compound represented by the above chemical formula 1 can be used as a building block for trifluoroalkylation or fluorine-18 labeled trifluoroalkylation substitution on a desired ligand.
[0049] In the present invention, the R 1 Inland R 6 Each may independently be hydrogen or a C1~C6 alkyl group, but is not limited thereto.
[0050] In the present invention, the above X 1 may be, but is not limited to, a chloro group, a bromo group, or an iodine group.
[0051] In the present invention, the copper complex compound represented by the chemical formula 1 may be a compound represented by the following chemical formula 6 or 7, but is not limited thereto.
[0052] [Chemical Formula 6]
[0053]
[0054] [Chemical Formula 7]
[0055]
[0056] In the above chemical formulas 6 and 7, R 1 Inland R 6 Wow X 1 is as defined above.
[0057] In the present invention, the copper complex compound represented by the chemical formula 1 may be a compound represented by any one of the following chemical formulas 11 to 13, but is not limited thereto.
[0058] [Chemical Formula 11]
[0059]
[0060] [Chemical Formula 12]
[0061]
[0062] [Chemical Formula 13]
[0063]
[0064] In the above chemical formulas 11 to 13, X 1 is as defined above.
[0065]
[0066] According to another embodiment of the present invention, there is provided a method for producing a copper complex compound represented by the above chemical formula 1.
[0067] In the manufacturing method of the present invention, the copper complex compound of the above chemical formula 1 can be manufactured by reacting a compound represented by the chemical formula 2 with a copper complex represented by the following chemical formula 3:
[0068] [Chemical Formula 2]
[0069]
[0070] In the above chemical formula 2, X 1 is as defined above.
[0071] [Chemical Formula 3]
[0072]
[0073] In the above chemical formula 3,
[0074] Z is a counterion, for example, NO3 - , CO3 - , ClO4 - , I - , SCN - or BF4 - It can be,
[0075] Cy1 to Cy6 and R 1 Inland R 6 Each is as defined above.
[0076] In the present invention, the copper complex represented by the chemical formula 3 may be a compound represented by the following chemical formula 4 or 5, but is not limited thereto.
[0077] [Chemical Formula 4]
[0078]
[0079] [Chemical Formula 5]
[0080]
[0081] In the above chemical formulas 4 and 5, R 1 Inland R 6 and Z are as defined above.
[0082] In the present invention, by reacting a compound represented by chemical formula 2 with a copper complex represented by chemical formula 4 or 5, a copper complex compound represented by chemical formula 6 or 7 can be produced.
[0083] [Chemical Formula 6]
[0084]
[0085] [Chemical Formula 7]
[0086]
[0087] In the above chemical formulas 6 and 7, R 1 Inland R 6 Wow X 1 is as defined above.
[0088] In the present invention, the copper complex represented by the chemical formula 3 may be a compound represented by any one of the following chemical formulas 8 to 10, but is not limited thereto.
[0089] [Chemical Formula 8]
[0090]
[0091] [Chemical Formula 9]
[0092]
[0093] [Chemical Formula 10]
[0094]
[0095] In the above chemical formulas 8 to 10, Z is as defined above.
[0096] In the present invention, by reacting a compound represented by chemical formula 2 with a copper complex represented by any one of chemical formulas 8 to 10, a copper complex compound represented by any one of chemical formulas 11 to 13 can be produced.
[0097] [Chemical Formula 11]
[0098]
[0099] [Chemical Formula 12]
[0100]
[0101] [Chemical Formula 13]
[0102]
[0103] In the above chemical formulas 11 to 13, X 1 is as defined above.
[0104] In the present invention, the copper complex represented by the above chemical formula 3 can be prepared by reacting a copper source and a ligand for preparing a copper complex in the presence of a base. Here, the copper source may be a copper halide such as CuF, CuCl, CuBr or CuI, or may be Cu(OTf)2, Cu(py)4(OTf)2, Cu(NCCH3)4, Cu(NCCH3)4·CF3SO3, Cu(MeCN)4BF4, [(CH3CN)4Cu]PF6, or (CF3SO3Cu)2·C6H6. In addition, the ligand for preparing the copper complex may be an N-donor ligand or an N,N'-donor ligand, and specific examples thereof include, but are not limited to, pyridine-2-carboxylic acid, dipivaloylmethane, N,N-dimethylglycine, 1,10-phenanthroline, proline, 2-thiophenecarboxylic acid, 2,2'-bipyridyl, ethyl 2-oxocyclohexanecarboxylate, 3,4,7,8-tetramethyl-1,10-phenanthroline, and N,N-dimethylethylenediamine. In the present invention, the ligand for preparing the copper complex may be added in an amount of 1 to 3 equivalents relative to the copper source, but is not limited thereto.
[0105] In addition, the manufacturing reaction of the copper complex described above in the present invention can be carried out in the presence of a base. The base to be added at this time includes an alkoxide, such as sodium tert-butoxide; an alkali metal amide, such as sodium amide, lithium diisopropylamide, and an alkali metal bis(trialkylsilyl)amide, such as lithium bis(trimethylsilyl)amide (LiHMDS) or sodium bis(trimethylsilyl)amide (NaHMDS); Tertiary amines (e.g., triethylamine, trimethylamine, 4-(dimethylamino)pyridine (DMAP), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,5-diazabicyclo[5.4.0]undec-5-ene (DBU); alkali or alkaline earth carbonates, bicarbonates or hydroxides (e.g., sodium, magnesium, calcium, barium, potassium carbonate, phosphate, hydroxide and bicarbonate) may be used, and preferably, NaH, LiH, KH, K2CO3, Na2CO3, Tl2CO3, Cs2CO3, K(OtBu), Li(OtBu), Na(OtBu), K(OAr), Na(OAr), triethylamine, or mixtures thereof may be used, but are not limited thereto. In the present invention, the base is used in an amount of 0.5 to 2 wt % relative to the copper source. It may be added in an amount of equivalent, preferably 1 to 1.5 equivalents, but is not limited thereto.
[0106] In the present invention, the reaction of the compound of the above chemical formula 2 and the copper complex can be performed in a solvent. Here, the solvent may be at least one selected from the group consisting of CH3CN, THF (tetrahydrofuran), CH2Cl2, DMF (N,N-dimethylformamide), DMSO (dimethyl sulfoxide), and mixtures thereof, but is not limited thereto.
[0107] In the present invention, the reaction of the compound of the above chemical formula 2 and the copper complex can be performed at room temperature (25±5°C) for 1 minute to 1 hour, preferably for 5 to 30 minutes, but is not limited thereto.
[0108] In the present invention, when reacting the compound of the above chemical formula 2 with the copper complex, the copper complex may be added in an amount of 0.5 to 2 equivalents, preferably 0.75 to 1.5 equivalents, relative to the compound, but is not limited thereto.
[0109] In the present invention, the manufacturing reaction of the copper complex and the reaction of the copper complex with the compound of Chemical Formula 2 may be performed sequentially, but may also be performed simultaneously. Furthermore, it may be performed as a one-pot reaction, but is not limited thereto.
[0110]
[0111] According to another embodiment of the present invention, the compound represented by the above chemical formula 2 or the copper complex compound represented by the above chemical formula 1 [ 18 F]fluoride ion or [ 19 [F] It relates to a method for producing trifluoroacetic acid represented by the following chemical formula 14 by reacting with fluoride ion:
[0112] [Chemical Formula 14]
[0113]
[0114] In the above chemical formula 14, X 2 Is 18 F or 19 It's F.
[0115] In the present invention, when the compound of the above chemical formula 2 or the copper complex compound represented by the above chemical formula 1 is reacted with fluoride ion, trifluoroacetic acid of the above chemical formula 14 can be produced.
[0116] In the present invention, the copper complex compound of the above chemical formula 1 can be prepared by reacting the compound of the above chemical formula 2 with the copper complex represented by the above chemical formula 3 as described above.
[0117] In the present invention, the above [ 18 F]fluoride ion or [ 19 [F]Fluoride ion may be added in an amount of 0.2 to 4 equivalents, preferably 0.2 to 2 equivalents, more preferably 0.2 to 1.5 equivalents, and most preferably 1 equivalent to the copper complex compound represented by the above chemical formula 1, but is not limited thereto.
[0118] In the present invention, the compound represented by the above chemical formula 2 or the copper complex compound represented by the above chemical formula 1 and [ 18 F]fluoride ion or [ 19[F] The reaction of fluoride ions is preferably carried out in the presence of a base to increase the reaction efficiency. Here, the base is an alkoxide, such as sodium tert-butoxide; an alkali metal amide, such as sodium amide, lithium diisopropylamide, and an alkali metal bis(trialkylsilyl)amide, such as lithium bis(trimethylsilyl)amide (LiHMDS) or sodium bis(trimethylsilyl)amide (NaHMDS); Tertiary amines (e.g., triethylamine, trimethylamine, 4-(dimethylamino)pyridine (DMAP), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,5-diazabicyclo[5.4.0]undec-5-ene (DBU); alkali or alkaline earth carbonates, bicarbonates or hydroxides (e.g., sodium, magnesium, calcium, barium, potassium carbonate, phosphate, hydroxide and bicarbonate) may be used, and preferably, NaH, LiH, KH, K2CO3, Na2CO3, Tl2CO3, Cs2CO3, K(OtBu), Li(OtBu), Na(OtBu), K(OAr), Na(OAr), triethylamine, or mixtures thereof may be used, but are not limited thereto. In the present invention, the base is a compound represented by the chemical formula 2 or 4. It may be added in an amount of 0.5 to 2 equivalents, preferably 0.75 to 1.5 equivalents, and most preferably 1 equivalent, but is not limited thereto.
[0119] In the present invention, the reaction of the compound represented by the above chemical formula 2 or the copper complex compound of the above chemical formula 1 and the fluoride ion can be performed in a solvent. Here, the solvent may be any one or more selected from the group consisting of CH3CN, THF (tetrahydrofuran), CH2Cl2, DMF (N,N-dimethylformamide), DMSO (dimethyl sulfoxide), and mixtures thereof, but is not limited thereto.
[0120] In addition, in the present invention, the reaction of the compound represented by the chemical formula 2 or the copper complex compound represented by the chemical formula 1 and the fluoride ion may be performed at a temperature of 50 to 100°C, preferably 60 to 80°C, more preferably 75°C, but is not limited thereto.
[0121] In addition, in the present invention, the reaction of the compound represented by the above chemical formula 2 or the copper complex compound represented by the above chemical formula 1 and the fluoride ion may be performed for 10 minutes to 6 hours, preferably 10 minutes to 1 hour, more preferably 10 minutes to 30 minutes, but is not limited thereto.
[0122] In the present invention, the above [ 18 F]Fluoride ion is 18O(p, n) from cyclotron 18 It can be obtained by F reaction, but is not limited thereto. In the present invention, if necessary, [ obtained by the above reaction 18 F]Fluoride K 2.2.2 By separating using an acetonitrile reaction solution containing dissolved K2CO3 [ 18 F]F - / H2 18 Step of obtaining O solution and the above [ 18 F]F - / H2 18 O Heating the solution K 2.2.2 / K[ 18 K obtained by performing an additional step of obtaining F]F 2.2.2 / K[ 18 You can use F]F.
[0123] In addition, in the present invention, the above [ 18 F]Fluoride ion is [ 18[F]Fluoride can be added to a reaction vessel together with a phase transfer catalyst and a base additive, and then used after blowing nitrogen at a temperature of 80 to 100°C to remove moisture. Here, the solvent can be methyl alcohol, acetonitrile, or a mixture thereof. The phase transfer catalyst can be Kryptofix. 2.2.2 (K 2.2.2 ) or 18-Crown-6 can be used, and the base additive can be selected from the group consisting of CsHCO3, Cs2CO3, KHCO3, K2CO3 and tetrabutylammonium salt, but is not limited thereto.
[0124] The manufacturing method of the present invention may further include a step of separating and purifying trifluoroacetic acid from the reaction mixture obtained after the reaction, if necessary. In the present invention, the separation and purification method is not particularly limited, but may be performed by passing the mixture through a cartridge containing an alumina adsorbent (sorbent substrate), and for example, may be performed using an Alumina N cartridge of Sep-pak®. Preferably, in terms of the efficiency of separation and purification of the trifluoroacetic acid, a cartridge filled with an alumina adsorbent in an amount of 250 to 2,000 mg may be passed through, and more preferably, a cartridge filled with an alumina adsorbent in an amount of 1,000 to 2,000 mg may be passed through, and for specific examples, an Alumina N light cartridge filled with an alumina adsorbent in an amount of 280 mg may be used, an Alumina N plus cartridge filled with an alumina adsorbent in an amount of 1,710 mg may be used, and more preferably, an Alumina N plus cartridge may be used, but is not limited thereto.
[0125] In the present invention, the above [ 19 F]Fluoride ions may be derived from, but are not limited to, metal fluoride compounds, [19 [F] Any fluoride source capable of supplying fluoride ions may be included without limitation. Here, the metal fluoride compounds include LiF, NaF, KF, CsF, RbF, TiF, AgF, AgF2, BaF2, CaF2, CuF2, CdF2, FeF2, HgF2, Hg2F2, MnF2, MgF2, NiF2, PbF2, SnF2, SrF2, XeF2, ZnF2, AlF2, BF2, BiF2, CeF2, CrF3, DyF3, EuF3, GaF3, GdF3, FeF3, HoF3, InF3, LaF3, LuF3, MnF3, NdF3, VOF3, PrF3, SbF3, ScF3, SmF3, TbF3, TiF3, TmF3, YF3, YbF3, TIF3, CeF4, GeF4, HfF4, SiF4, SnF4, TiF4, VF4, ZrF4, NbF5, SbF5, TaF5, BiF5, MoF6, ReF6, SF6, and WF6 can be used, but are not limited thereto.
[0126] The manufacturing method of the present invention may further include a step of formulating the reaction mixture obtained after the reaction, if necessary. In the present invention, the formulation method is not particularly limited, but may be performed by passing the mixture through a cartridge containing a polymer adsorbent (copolymer sorboent), and may be performed using, for example, an Oasis WAX Plus short cartridge, but is not limited thereto.
[0127] When using the manufacturing method of the present invention, trifluoroacetic acid can be manufactured in a high yield. In the present invention, the compound represented by the above chemical formula 2 or the copper complex compound of the above chemical formula 1 [ 18 [F] When reacted with fluoride ion, trifluoroacetic acid labeled with fluorine-18 can be produced, and the fluorine-18 labeled trifluoroacetic acid produced in this way can be used to produce additional radiopharmaceuticals.
[0128]
[0129] According to another embodiment of the present invention, there is provided a method for trifluoroalkylating a ligand using a copper complex compound represented by the above chemical formula 1.
[0130] The trifluoroalkylation method of the present invention may include a step of reacting a ligand with a copper complex compound of the above chemical formula 1 in the presence of a fluoride ion to trifluoroalkylate the ligand.
[0131] In the present invention, the fluoride ion is [ 18 F]fluoride ion or [ 19 F] may be a fluoride ion. [ as a fluoride ion 18 When using F]fluoride ions, the ligand can be labeled with the radioisotope fluorine-18.
[0132] In the present invention, the above [ 18 F]Fluoride ion is 18O(p, n) from cyclotron 18 It can be obtained by F reaction, but is not limited thereto. In the present invention, if necessary, [ obtained by the above reaction 18 F]Fluoride K 2.2.2 By separating using an acetonitrile reaction solution containing dissolved K2CO3 [ 18 F]F - / H2 18 Step of obtaining O solution and the above [ 18 F]F - / H2 18 O Heating the solution K 2.2.2 / K[ 18 K obtained by performing an additional step of obtaining F]F 2.2.2 / K[ 18 You can use F]F.
[0133] In addition, in the present invention, the above [ 18 F]Fluoride ion is [18 F]Fluoride can be added to a reaction vessel together with a phase transfer catalyst and a base additive, and then used after blowing nitrogen at a temperature of 80 to 100°C to remove moisture. Here, the solvent can be methyl alcohol, acetonitrile, or a mixture thereof. The phase transfer catalyst can be K 2.2.2 Alternatively, 18-Crown-6 may be used, and the base additive may be selected from the group consisting of CsHCO3, Cs2CO3, KHCO3, K2CO3, and tetrabutylammonium salt, but is not limited thereto.
[0134] In the present invention, the above [ 19 F]Fluoride ions may be derived from, but are not limited to, metal fluoride compounds, [ 19 [F] Any fluoride source capable of supplying fluoride ions may be included without limitation. Here, the metal fluoride compounds include LiF, NaF, KF, CsF, RbF, TiF, AgF, AgF2, BaF2, CaF2, CuF2, CdF2, FeF2, HgF2, Hg2F2, MnF2, MgF2, NiF2, PbF2, SnF2, SrF2, XeF2, ZnF2, AlF2, BF2, BiF2, CeF2, CrF3, DyF3, EuF3, GaF3, GdF3, FeF3, HoF3, InF3, LaF3, LuF3, MnF3, NdF3, VOF3, PrF3, SbF3, ScF3, SmF3, TbF3, TiF3, TmF3, YF3, YbF3, TIF3, CeF4, GeF4, HfF4, SiF4, SnF4, TiF4, VF4, ZrF4, NbF5, SbF5, TaF5, BiF5, MoF6, ReF6, SF6, and WF6 can be used, but are not limited thereto.
[0135] In the present invention, the fluoride ion may be added in an amount of 0.2 to 4 equivalents, preferably 0.2 to 3 equivalents, and more preferably 1 to 3 equivalents, relative to the copper complex compound represented by the chemical formula 1, but is not limited thereto.
[0136] In the present invention, it is preferable that the reaction be performed in the presence of a base to increase the reaction efficiency. Here, the base is an alkoxide, such as sodium tert-butoxide; an alkali metal amide, such as sodium amide, lithium diisopropylamide, and an alkali metal bis(trialkylsilyl)amide, such as lithium bis(trimethylsilyl)amide (LiHMDS) or sodium bis(trimethylsilyl)amide (NaHMDS); Tertiary amines (e.g., triethylamine, trimethylamine, 4-(dimethylamino)pyridine (DMAP), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,5-diazabicyclo[5.4.0]undec-5-ene (DBU); alkali or alkaline earth carbonates, bicarbonates or hydroxides (e.g., sodium, magnesium, calcium, barium, potassium carbonate, phosphate, hydroxide and bicarbonate) may be used, and preferably, NaH, LiH, KH, K2CO3, Na2CO3, Tl2CO3, Cs2CO3, K(OtBu), Li(OtBu), Na(OtBu), K(OAr), Na(OAr), triethylamine, or mixtures thereof may be used, but are not limited thereto. In the present invention, the base is 0.5 to the copper complex compound of the above chemical formula 1. It may be added in an amount of 0.5 to 4 equivalents, preferably 0.5 to 3 equivalents, but is not limited thereto.
[0137] In the present invention, the reaction of the copper complex compound of the above chemical formula 1 and the fluoride ion can be performed in a solvent. Here, the solvent may be any one or more selected from the group consisting of CH3CN, THF (tetrahydrofuran), CH2Cl2, DMF (N,N-dimethylformamide), DMSO (dimethyl sulfoxide), and mixtures thereof, but is not limited thereto.
[0138] In the present invention, even if a copper complex compound of the same chemical formula 1 is used, a trifluoromethyl group or a trifluoroethyl group may be substituted on the ligand depending on the ligand and reaction conditions.
[0139] Trifluoromethylation method
[0140] In the present invention, the ligand to be used to transfer the trifluoromethyl group is an aryl (e.g., C6~C) substituted by at least one substituent selected from the group consisting of a halogen, a boronic acid group (-B(OH)2), and a boronic acid pinacol ester group (-Bpin). 14 As a compound containing an aryl) or heteroaryl (e.g., heteroaryl having 5 to 14 nuclear atoms) structure, it can be included without limitation as long as it is preferably used for the purpose of diagnosing or treating a disease or can be used for imaging.
[0141] In the present invention, the ligand including the halogen-substituted aryl or heteroaryl structure may include a phenyl structure substituted with a fluoro group, a chloro group, a bromo group, an iodine group, a boronic acid group (-B(OH)2), or a boronic acid pinacol ester group (-Bpin), and may be, for example, a compound represented by the following chemical formula 15, but is not limited thereto.
[0142] [Chemical Formula 15]
[0143]
[0144] In the above chemical formula 15,
[0145] X is a halogen, a boronic acid group or a boronic acid pinacol ester group, preferably a halogen,
[0146] Y 1 is N or C(R 8 ) and
[0147] m is an integer from 0 to 4,
[0148] R 7 Silver halogen, nitro, cyano group, C1~C6 alkyl group, C6~C 14 Aryl group, C1~C6 alkoxy group, -C(=O)-R 9 , or -NR 10 C(=O)-R 11 and the above R 7 In this case, they are the same or different from each other,
[0149] R 8 is hydrogen or a C1~C6 alkyl group,
[0150] R 9 is hydrogen, an amine group (-NH2), a C1~C6 alkyl group, or a C1~C6 alkoxy group,
[0151] R 10 and R 11 are each independently hydrogen or a C1~C6 alkyl group.
[0152] Non-limiting examples of the ligand including the halogen-substituted aryl or heteroaryl structure in the present invention may be selected from compounds having the structures below, but are not limited thereto.
[0153]
[0154] In the above chemical formula, X is a halogen, a boronic acid group, or a boronic acid pinacol ester group.
[0155] The trifluoromethylation method of the present invention may include a step of reacting the above-described ligand, the copper complex compound of the above-described chemical formula 1, and a fluoride ion source.
[0156] In the present invention, the halogen, boronic acid group or boronic acid pinacol ester group in the ligand can be substituted with a trifluoromethyl group derived from the compound of chemical formula 1 by a reaction represented by the reaction scheme 1 below.
[0157] [Reaction Formula 1]
[0158]
[0159] In the above reaction scheme 1, each group is as defined above.
[0160] In the present invention, the fluoride ion may be added in an amount of 0.2 to 4 equivalents, preferably 1 to 3 equivalents, to the copper complex compound represented by the chemical formula 1, but is not limited thereto.
[0161] In the present invention, the reaction is preferably carried out in the presence of a base to increase the reaction efficiency. The base may be added in an amount of 0.5 to 4 equivalents, or 0.5 to 3 equivalents, relative to the copper complex compound of the above chemical formula 1. Preferably, during the reaction, [ 18 When using F]fluoride ion, the base may be added in an amount of 0.5 to 1.5 equivalents, or 0.5 to 1 equivalent, to the copper complex compound of the above chemical formula 1. In addition, during the reaction, [ 19 When using F]fluoride ion, the base may be added in an amount of 1 to 4 equivalents, or 1 to 3 equivalents, relative to the copper complex compound of the above chemical formula 1.
[0162] In the present invention, the reaction may be carried out at a temperature of 50 to 200°C, but is not limited thereto. Preferably, during the reaction, fluoride ions are used. 18[F] When using fluoride ion, the reaction can be carried out at a temperature of 100 to 200°C, preferably 125 to 175°C. In addition, during the reaction, [ 19 When using F]fluoride ions, the reaction can be carried out at a temperature of 50 to 200°C, preferably 50 to 150°C or 60 to 80°C.
[0163] In the present invention, the reaction may be carried out for 5 to 120 minutes, but is not limited thereto. Preferably, during the reaction, fluoride ions are used [ 18 [F] When using fluoride ions, the reaction can be carried out for 10 to 30 minutes. In addition, during the reaction, [ 19 When using F]fluoride ions, the reaction can be carried out for 30 to 100 minutes.
[0164] A trifluoromethylation method according to an example of the present invention comprises the above ligand and the copper complex compound of the above chemical formula 1 and [ 19 [F] may include a step of reacting a fluoride ion source. At this time, the above [ 19 [F] The fluoride ion source may be added in an amount of 1 to 3 equivalents relative to the copper complex compound of the above chemical formula 1. In addition, the reaction may be performed at a reaction temperature of 50 to 150° C. for 30 to 100 minutes in the presence of a base in an amount of 1 to 4 equivalents relative to the copper complex compound of the above chemical formula 1, but is not limited thereto.
[0165] A trifluoromethylation method according to an example of the present invention comprises the above ligand and the copper complex compound of the above chemical formula 1 and [ 18[F] A step of reacting a fluoride ion source may be included. At this time, the reaction may be performed at a reaction temperature of 100 to 200° C. for 10 minutes to 30 minutes in the presence of a base in an amount of 0.5 to 1.5 equivalents relative to the copper complex compound of the above chemical formula 1, but is not limited thereto.
[0166] Non-limiting examples of ligands substituted with a trifluoromethyl group according to the method of the present invention may be selected from compounds having the structures below, but are not limited thereto.
[0167]
[0168] In the above chemical formula, X 2 Is 18 F or 19 It's F.
[0169] Trifluoroethylation method
[0170] In the present invention, the ligand to be used to transfer the trifluoroethyl group includes a primary amine group (-NH2) or a secondary amine group (-NRH; here, R may be any substituent) in its structure, and preferably, any ligand that can be used for the purpose of diagnosing or treating a disease or for imaging may be included without limitation.
[0171] Non-limiting examples of the ligand containing the amine group in the present invention include N-methyl-3-phenylpropan-1-amine, N-methylbenzylamine, N,N-diethyl-amine, 1,2,3,4-tetrahydroisoquinoline, 1-methyl-4-piperazine, 4-morpholine, ethyl piperidine-2-carboxylate, piperidin-4-ol, N-(2-(6-methoxy)indolin-3-yl)ethyl)acetamide, indole, It may include, but is not limited to, compounds such as 6-bromoindoline, 4-methylindoline, and N-methylbenzenamine.
[0172] The trifluoroethylation method of the present invention may include a step of reacting a copper complex compound of the above chemical formula 1 with a fluoride ion source to produce trifluoroacetic acid represented by the above chemical formula 14; and a step of reacting the trifluoroacetic acid with the above ligand.
[0173] In the trifluoroethylation method of the present invention, the step of generating the trifluoroacetic acid and the step of reacting the trifluoroacetic acid with the ligand can be performed as two separate steps, but can be performed continuously in one reactor.
[0174] In the present invention, any hydrogen (H) of the amine group in the ligand can be replaced with a trifluoroethyl group derived from trifluoroacetic acid of chemical formula 14 by the reaction represented by the reaction scheme 2 below.
[0175] [Reaction Formula 2]
[0176]
[0177] In the above reaction formula 2,
[0178] means the part where the amine group is connected in the above ligand,
[0179] R 13 is hydrogen or any substituent, such as C1~C6 alkyl group, C6~C 14 It may vary depending on the structure of the ligand, such as an aryl group, and is not particularly limited.
[0180] Also, X 2 Is 18 F or 19 It's F.
[0181] In the present invention, the reaction is preferably performed in the presence of a base to increase reaction efficiency. The base may be added in an amount of 1 to 4 equivalents, or 1 to 3 equivalents, relative to the copper complex compound of Chemical Formula 1, but is not limited thereto.
[0182] In the present invention, the reaction of the copper complex compound represented by the above chemical formula 1 and the fluoride ion can be performed at a temperature of 50 to 100°C, preferably 60 to 80°C, more preferably 75°C, but is not limited thereto.
[0183] In addition, in the present invention, the reaction of the copper complex compound represented by the chemical formula 1 and the fluoride ion may be performed for 10 minutes to 6 hours, preferably 10 minutes to 1 hour, and more preferably 10 minutes to 30 minutes, but is not limited thereto.
[0184] In the present invention, the reaction of the trifluoroacetic acid of the above chemical formula 1 and the ligand containing an amine group can be performed in the presence of a reducing agent. At this time, examples of the reducing agent that can be used include sodium borohydride (NaBH4), sodium cyanoborohydride (NaCNBH3), sodium acetate cyanoborohydride (NaBH3OAc), sodium triacetoxyborohydride, lithium borohydride (LiBH4), lithium aluminum hydride (LiAlH4), (i-Bu2AlH)2, L-selectride, K-selectride, SnCl2, phenylsilane, Et3SiH, and mixtures thereof, and is preferably sodium cyanoborohydride (NaCNBH3), but is not limited thereto. In the present invention, the reducing agent may be added in an amount of 1 to 5 equivalents relative to the ligand, and preferably in an amount of 2 to 5 equivalents, but is not limited thereto.
[0185] In the present invention, the reaction of the trifluoroacetic acid of the above chemical formula 1 and the ligand containing an amine group may be performed at, but is not limited to, 10 to 150°C, preferably 25 to 150°C, more preferably 100 to 150°C, and most preferably 120°C.
[0186] In the present invention, the reaction of the trifluoroacetic acid of the above chemical formula 1 and the ligand containing an amine group may be performed for 5 to 120 minutes, preferably 15 to 60 minutes, and more preferably 20 to 40 minutes, but is not limited thereto.
[0187] Non-limiting examples of ligands substituted with a trifluoroethyl group according to the method of the present invention may be selected from compounds having the structures below, but are not limited thereto.
[0188]
[0189] In the above chemical formula, X 2 Is 18 F or 19 It's F.
[0190] According to the method of the present invention, a trifluoroalkyl group, particularly a trifluoromethyl group or a trifluoroethyl group, can be transferred to the desired ligand, and the fluoride ion [ 18 When using F]fluoride ion, a ligand can be prepared in which a trifluoroalkyl group labeled with fluorine-18 is introduced. In this way, -CF2[ 18 Ligands having the group [F] have excellent stability in the body when administered into the body, and also have excellent lipophilicity and cell penetration.
[0191]
[0192] According to another embodiment of the present invention, the trifluoroalkylation method is used to ligand [ 18 [F]Regarding a method for manufacturing a radiopharmaceutical substituted with a fluoroalkyl group.
[0193] In the present invention, fluoride ion [ 18 When reacting with F]fluoride ion, the ligand [ 18 F]trifluoromethyl group or [ 18 By substituting the F]trifluoroethyl group, fluorine-18 labeled trifluoromethyl (-CF2[ 18 F]) or trifluoroethyl (-CH2CF2[ 18 [F]) can be used to manufacture radioactive pharmaceuticals.
[0194]
[0195] According to another embodiment of the present invention, the present invention relates to a compound represented by any one of the following chemical formulae 16 to 30, or a pharmaceutically acceptable salt or solvate thereof, prepared by the above method:
[0196]
[0197] The present invention provides pharmaceutically acceptable salts of compounds represented by the above chemical formulae 16 to 30. The pharmaceutically acceptable salts are salts generally considered by those skilled in the art to be suitable for medical applications (e.g., because such salts are not harmful to a subject that can be treated with the salts), or salts that cause acceptable side effects within the respective treatments. Typically, the pharmaceutically acceptable salts are salts considered acceptable by regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or the Pharmaceuticals and Medical Devices Agency (PMDA) of the Ministry of Health, Labour and Welfare of Japan. However, the present invention also encompasses salts of the compounds of the present invention that are not pharmaceutically acceptable in themselves, for example, as intermediates in the preparation of the compounds of the present invention or physiologically functional derivatives thereof, or as intermediates in the preparation of pharmaceutically acceptable salts of the compounds of the present invention or physiologically functional derivatives thereof. The salts include water-insoluble salts, and in particular, water-soluble salts.
[0198] In each case, a person skilled in the art can readily determine whether a particular compound according to the invention or a physiologically functional derivative thereof is capable of forming a salt, i.e. whether the compound according to the invention or a physiologically functional derivative thereof has a group capable of carrying a charge, such as, for example, an amino group, a carboxylic acid group, etc.
[0199] Exemplary salts of the compounds of the present invention are acid addition salts or salts with bases, particularly pharmaceutically acceptable inorganic and organic acid addition salts and salts with bases commonly used in pharmacy, which are water-insoluble or particularly water-soluble acid addition salts. Depending on the substituents of the compounds of the present invention, salts with bases may also be suitable. Acid addition salts can be formed, for example, by mixing a solution of a compound of the present invention with a solution of a pharmaceutically acceptable acid, such as hydrochloric acid, sulfuric acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Similarly, pharmaceutically acceptable base addition salts include alkali metal salts (e.g., sodium or potassium salts); alkaline earth metal salts (e.g., calcium or magnesium salts); and salts formed with suitable organic ligands (e.g., ammonium, quaternary ammonium and amine cations formed using counter anions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, alkyl sulfonates and aryl sulfonates).Illustrative examples of pharmaceutically acceptable salts include acetate, adipate, alginate, arginate, ascorbate, aspartate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, butyrate, calcium edetate, camphorate, camphorsulfonate, camsylate, carbonate, chloride, citrate, digluconate, dihydrochloride, dodecylsulfate, edetate, edisylate, ethanesulfonate, formate, fumarate, galactate, galacturonate, gluconate, glutamate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hexylresorcinate, hydrobromide, hydrochloride, hydroiodide, Including but not limited to 2-hydroxy-ethanesulfonate, hydroxynaphthoate, iodide, isobutyrate, isothionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, mandelate, methanesulfonate (mesylate), methyl sulfate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pantothenate, pectinate, persulfate, 3-phenylpropionate, phosphate / diphosphate, phthalate, picrate, pivalate, polygalacturonate, propionate, salicylate, stearate, sulfate, suberate, succinate, tannate, tartrate, tosylate, undecanoate, valerate, etc.
[0200] Salts which are not pharmaceutically acceptable and which may be obtained, for example, as process products during the preparation of the compounds according to the invention on an industrial scale, are also encompassed by the present invention and, if desired, can be converted into pharmaceutically acceptable salts by methods known to those skilled in the art.
[0201] Meanwhile, the compounds according to the present invention may have an asymmetric carbon center and thus may exist as R or S isomers or racemic compounds, and all of these optical isomers and mixtures may be included in the scope of the present invention.
[0202] In addition, the compounds of the present invention, as well as their salts, may contain varying amounts of solvent, for example, when isolated in crystalline form. Accordingly, solvates, particularly hydrates, of the compounds of the present invention, as well as solvates, particularly hydrates, of salts of the compounds of the present invention, may be included within the scope of the present invention. More particularly, the present invention may include hydrates of the compounds, salts, and / or physiologically functional derivatives according to the present invention, which contain one, two, or half water molecules with respect to the stoichiometry.
[0203]
[0204] According to another embodiment of the present invention, there is provided a pharmaceutical composition for preventing, improving or treating a disease, comprising as an active ingredient a compound represented by the following chemical formula 29, or a pharmaceutically acceptable salt or solvate thereof:
[0205] [Chemical Formula 29]
[0206]
[0207] According to another embodiment of the present invention, there is provided a method for preventing, improving or treating a disease, comprising administering to a subject in need of administration a pharmaceutically effective amount of a compound represented by the above chemical formula 29, or a pharmaceutically acceptable salt or solvate thereof.
[0208] In the present invention, the disease may be cancer, and the cancer may be melanoma, fallopian tube cancer, brain cancer, small intestine cancer, esophageal cancer, lymphoma, gallbladder cancer, blood cancer, thyroid cancer, endocrine cancer, oral cancer, liver cancer, biliary tract cancer, colon cancer, rectal cancer, cervical cancer, ovarian cancer, kidney cancer, stomach cancer, duodenal cancer, prostate cancer, breast cancer, brain tumor, lung cancer, undifferentiated thyroid cancer, uterine cancer, colon cancer, bladder cancer, ureteral cancer, pancreatic cancer, bone / soft tissue sarcoma, skin cancer, non-Hodgkin's lymphoma, Hodgkin's lymphoma, multiple myeloma, leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia or solitary myeloma, and is preferably prostate cancer, but is not limited thereto.
[0209] In the present invention, the above-mentioned individual is an individual that has developed or is suspected of developing the above-mentioned disease, and the individual suspected of developing the disease means all animals including humans, monkeys, cows, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, rats, rabbits or guinea pigs that have developed or can develop the disease, but an individual that can be treated with the effective substance provided in the present invention is included without limitation.
[0210] In the present invention, the "pharmaceutical composition" may be characterized as being in the form of a capsule, tablet, granule, injection, ointment, powder or beverage, and the pharmaceutical composition may be characterized as being intended for animals, specifically humans.
[0211] The pharmaceutical compositions described above are not limited thereto, but may be formulated and used in the form of oral dosage forms such as powders, granules, capsules, tablets, and aqueous suspensions, as well as external preparations, suppositories, and sterile injectable solutions, each according to a conventional method. The pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers may include binders, lubricants, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, coloring agents, fragrances, etc. for oral administration, and buffers, preservatives, analgesics, solubilizers, isotonic agents, stabilizers, etc. for injections. For topical administration, bases, excipients, lubricants, preservatives, etc. may be used. The formulations of the pharmaceutical composition of the present invention may be prepared in various ways by mixing with the pharmaceutically acceptable carriers described above. For example, for oral administration, it can be manufactured in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, etc., and for injections, it can be manufactured in the form of unit dose ampoules or multiple doses. In addition, it can be formulated in the form of solutions, suspensions, tablets, capsules, sustained-release preparations, etc.
[0212] Meanwhile, examples of carriers, excipients, and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, malditol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, or mineral oil. In addition, fillers, anticoagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives, and the like may be additionally included.
[0213] In the present invention, the pharmaceutical composition may further comprise a radical scavenger in addition to the compound of the present invention or a pharmaceutically acceptable salt thereof. The radical scavenger may be used to prevent radiolysis. Radiolysis is a process in which the ionization of oxygen or water molecules induced by radionuclides forms other reactive species such as superoxide, hydrogen peroxide, hydrogen radicals, ozone, and hydroxyl radicals. These reactive species can also cause damage to DNA and other cellular structures. In some embodiments, the radical scavenger is an antioxidant selected from carnosic acid, green tea extract, apigenin, diosmin, rosmarinic acid, lipoic acid, beta-carotene, L-ascorbic acid (vitamin C), N-acetylcysteine (NAC), δ-tocopherol, rutin, amifostine, resveratrol, gentisic acid, and gallic acid. In some embodiments, the radical scavenger may be an antioxidant selected from, but not limited to, gallic acid, L-ascorbic acid, and N-acetyl cysteine (NAC).
[0214] Routes of administration of the pharmaceutical composition according to the present invention include, but are not limited to, oral, intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal. Oral or parenteral administration is preferred, and the term "parenteral" includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection or infusion techniques. The pharmaceutical composition of the present invention may also be administered in the form of a suppository for rectal administration.
[0215] In addition, the pharmaceutical composition may vary depending on various factors including the activity of the specific compound used, age, body weight, general health, sex, dosage form, administration time, administration route, excretion rate, drug combination, and severity of the specific disease to be prevented or treated, and the dosage of the pharmaceutical composition may vary depending on the patient's condition, body weight, degree of disease, drug form, administration route, and period, but may be appropriately selected by those skilled in the art, and may be administered at 0.0001 to 50 mg / kg or 0.001 to 50 mg / kg per day. Administration may be administered once a day or divided into several times. The dosage does not limit the scope of the present invention in any way. The pharmaceutical composition according to the present invention may be formulated as a pill, a sugar-coated tablet, a capsule, a liquid, a gel, a syrup, a slurry, or a suspension.
[0216] The pharmaceutical composition of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.
[0217]
[0218] According to another embodiment of the present invention, the present invention relates to an imaging composition or a disease diagnostic composition comprising a compound represented by any one of the chemical formulae 16 to 30, or a pharmaceutically acceptable salt or solvate thereof, as an active ingredient.
[0219] According to another embodiment of the present invention, the present invention relates to an imaging method or a method for diagnosing a disease, comprising a step of administering to a subject in need of administration a pharmaceutically effective amount of a compound represented by any one of the chemical formulae 16 to 30, or a pharmaceutically acceptable salt or solvate thereof.
[0220] In the present invention, the subject is an object that has developed or is suspected of developing the desired disease and requires imaging of tissue, and means all animals including humans, monkeys, cows, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, rats, rabbits or guinea pigs that have developed or can develop the disease, but an object that can be treated with the effective substance provided in the present invention is included without limitation.
[0221] In the present invention, when a pharmaceutical composition containing a compound according to the present invention is administered to a subject of interest, the compound binds to lesion tissue, such as tumor tissue or cancer tissue, thereby enabling imaging. The technique for imaging in the present invention may be, but is not limited to, positron emission tomography (PET), or a combination of positron emission tomography and computed tomography (PET-CT).
[0222] Therefore, when using the compound of the present invention, it is possible to diagnose whether or not a disease such as cancer or tumor has developed in a subject or whether there is a possibility of such development.
[0223] When using the copper complex compound provided in the present invention, a trifluoroalkyl group can be substituted on the desired ligand with high yield. In addition, the reaction is carried out with a fluoride ion [ 18 When using F]fluoride ion, -CF2[ 18 F] can be substituted. Like this -CF2[ 18 Radiopharmaceuticals substituted with [F] have the advantages of excellent stability in the body, lipophilicity, and cell penetration.
[0224] Figure 1 shows the copper complex compound in Experimental Example 2 and [ 19 The amount of trifluoroacetic acid produced in the reaction mixture depends on the reaction time of the F]fluoride ion. 19 This shows the results of analysis using F-NMR.
[0225] Figure 2 shows the copper complex compound in Experimental Example 4 and [ 18 [F]The results of HPLC analysis of the reaction mixture of fluoride ions are shown.
[0226] Figure 3 shows the copper complex compound in Experimental Example 5 and [ 18 This shows the results of HPLC analysis on the filtrate obtained after passing the reaction mixture of F]fluoride ions through a Sep-pak cartridge.
[0227] Figure 4 shows the copper complex compound in Experimental Example 5 and [ 18 This shows the results of HPLC analysis on the elution filtrate obtained after passing the reaction mixture of F]fluoride ions through a Sep-pak cartridge and then passing it through a WAX cartridge.
[0228] Figure 5 shows a ligand containing an amine group in Experimental Example 6. 18 This shows the results of HPLC analysis of the product obtained after reacting F-TFA.
[0229] Figure 6 shows a copper complex compound and a ligand containing a halogen-substituted argyle group in Experimental Example 7 and [ 18 This shows the results of HPLC analysis on the product obtained after reacting with F]fluoride ion.
[0230] According to one embodiment of the present invention, the present invention relates to a building block composition for trifluoroalkylation comprising a copper complex compound represented by the following chemical formula 1.
[0231] [Chemical Formula 1]
[0232]
[0233] In the above chemical formula 1,
[0234] Cy1 to Cy4 are each independently a heteroaryl or heterocycloalkenyl ring having 4 to 8 atoms,
[0235] Cy5 and Cy6 are each independently a cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl or heterocycloalkenyl ring having 0 to 8 atoms, (wherein 0 atoms means no ring).
[0236] R 1 Inland R 6 are each independently hydrogen, halogen, nitro, C1~C6 alkyl group or C6~C 14 As an aryl group, it is a mono-substituent or a multi-substituent that is the same or different,
[0237] X 1 may be a halogen other than a fluoro group.
[0238] In the present invention, the copper complex compound represented by the chemical formula 1 may be a compound represented by the following chemical formula 6 or 7, but is not limited thereto.
[0239] [Chemical Formula 6]
[0240]
[0241] [Chemical Formula 7]
[0242]
[0243] In the above chemical formulas 6 and 7, R 1 Inland R 6 Wow X 1 is as defined above.
[0244] In the present invention, the copper complex compound represented by the chemical formula 1 may be a compound represented by any one of the following chemical formulas 11 to 13, but is not limited thereto.
[0245] [Chemical Formula 11]
[0246]
[0247] [Chemical Formula 12]
[0248]
[0249] [Chemical Formula 13]
[0250]
[0251] In the above chemical formulas 11 to 13, X 1 is as defined above.
[0252] According to another embodiment of the present invention, a compound represented by the following chemical formula 2 or a copper complex compound represented by the above chemical formula 1 is provided. 18 F]fluoride ion or [ 19 [F] It relates to a method for producing trifluoroacetic acid represented by the following chemical formula 14 by reacting with fluoride ion:
[0253] [Chemical Formula 2]
[0254]
[0255] [Chemical Formula 14]
[0256]
[0257] In the above chemical formulas 2 and 14, X 1 is as defined above, and X 2 Is 18 F or 19 It's F.
[0258] In the present invention, when the compound of the above chemical formula 2 or the copper complex compound represented by the above chemical formula 1 is reacted with fluoride ion, trifluoroacetic acid of the above chemical formula 14 can be produced.
[0259] In the present invention, the copper complex compound of the above chemical formula 1 can be prepared by reacting the compound of the above chemical formula 2 with the copper complex represented by the above chemical formula 3 as described above.
[0260] In the present invention, the above [ 18 F]fluoride ion or [ 19[F]Fluoride ion may be added in an amount of 0.2 to 4 equivalents, preferably 0.2 to 2 equivalents, more preferably 0.2 to 1.5 equivalents, and most preferably 1 equivalent to the copper complex compound represented by the above chemical formula 1, but is not limited thereto.
[0261] In the present invention, the compound represented by the above chemical formula 2 or the copper complex compound represented by the above chemical formula 1 and [ 18 F]fluoride ion or [ 19 [F] The reaction of fluoride ions is preferably carried out in the presence of a base to increase the reaction efficiency. Here, the base is an alkoxide, such as sodium tert-butoxide; an alkali metal amide, such as sodium amide, lithium diisopropylamide, and an alkali metal bis(trialkylsilyl)amide, such as lithium bis(trimethylsilyl)amide (LiHMDS) or sodium bis(trimethylsilyl)amide (NaHMDS); Tertiary amines (e.g., triethylamine, trimethylamine, 4-(dimethylamino)pyridine (DMAP), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,5-diazabicyclo[5.4.0]undec-5-ene (DBU); alkali or alkaline earth carbonates, bicarbonates or hydroxides (e.g., sodium, magnesium, calcium, barium, potassium carbonate, phosphate, hydroxide and bicarbonate) may be used, and preferably, NaH, LiH, KH, K2CO3, Na2CO3, Tl2CO3, Cs2CO3, K(OtBu), Li(OtBu), Na(OtBu), K(OAr), Na(OAr), triethylamine, or mixtures thereof may be used, but are not limited thereto. In the present invention, the base is a compound represented by the chemical formula 2 or 4. It may be added in an amount of 0.5 to 2 equivalents, preferably 0.75 to 1.5 equivalents, and most preferably 1 equivalent, but is not limited thereto.
[0262] In the present invention, the reaction of the compound represented by the above chemical formula 2 or the copper complex compound of the above chemical formula 1 and the fluoride ion can be performed in a solvent. Here, the solvent may be any one or more selected from the group consisting of CH3CN, THF (tetrahydrofuran), CH2Cl2, DMF (N,N-dimethylformamide), DMSO (dimethyl sulfoxide), and mixtures thereof, but is not limited thereto.
[0263] In addition, in the present invention, the reaction of the compound represented by the chemical formula 2 or the copper complex compound represented by the chemical formula 1 and the fluoride ion may be performed at a temperature of 50 to 100°C, preferably 60 to 80°C, more preferably 75°C, but is not limited thereto.
[0264] In addition, in the present invention, the reaction of the compound represented by the above chemical formula 2 or the copper complex compound represented by the above chemical formula 1 and the fluoride ion may be performed for 10 minutes to 6 hours, preferably 10 minutes to 1 hour, more preferably 10 minutes to 30 minutes, but is not limited thereto.
[0265] In the present invention, the above [ 18 F]Fluoride ion is 18O(p, n) from cyclotron 18 It can be obtained by F reaction, but is not limited thereto. In the present invention, if necessary, [ obtained by the above reaction 18 F]Fluoride K 2.2.2 By separating using an acetonitrile reaction solution containing dissolved K2CO3 [ 18 F]F - / H2 18 Step of obtaining O solution and the above [ 18 F]F - / H2 18 O Heating the solution K2.2.2 / K[ 18 K obtained by performing an additional step of obtaining F]F 2.2.2 / K[ 18 You can use F]F.
[0266] In addition, in the present invention, the above [ 18 F]Fluoride ion is [ 18 [F]Fluoride can be added to a reaction vessel together with a phase transfer catalyst and a base additive, and then used after blowing nitrogen at a temperature of 80 to 100°C to remove moisture. Here, the solvent can be methyl alcohol, acetonitrile, or a mixture thereof. The phase transfer catalyst can be Kryptofix. 2.2.2 (K 2.2.2 ) or 18-Crown-6 can be used, and the base additive can be selected from the group consisting of CsHCO3, Cs2CO3, KHCO3, K2CO3 and tetrabutylammonium salt, but is not limited thereto.
[0267] The manufacturing method of the present invention may further include a step of separating and purifying trifluoroacetic acid from the reaction mixture obtained after the reaction, if necessary. In the present invention, the separation and purification method is not particularly limited, but may be performed by passing the mixture through a cartridge containing an alumina adsorbent (sorbent substrate), and for example, may be performed using an Alumina N cartridge of Sep-pak®. Preferably, in terms of the efficiency of separation and purification of the trifluoroacetic acid, a cartridge filled with an alumina adsorbent in an amount of 250 to 2,000 mg may be passed through, and more preferably, a cartridge filled with an alumina adsorbent in an amount of 1,000 to 2,000 mg may be passed through, and for specific examples, an Alumina N light cartridge filled with an alumina adsorbent in an amount of 280 mg may be used, an Alumina N plus cartridge filled with an alumina adsorbent in an amount of 1,710 mg may be used, and more preferably, an Alumina N plus cartridge may be used, but is not limited thereto.
[0268] In the present invention, the above [ 19 F]Fluoride ions may be derived from, but are not limited to, metal fluoride compounds, [ 19[F] Any fluoride source capable of supplying fluoride ions may be included without limitation. Here, the metal fluoride compounds include LiF, NaF, KF, CsF, RbF, TiF, AgF, AgF2, BaF2, CaF2, CuF2, CdF2, FeF2, HgF2, Hg2F2, MnF2, MgF2, NiF2, PbF2, SnF2, SrF2, XeF2, ZnF2, AlF2, BF2, BiF2, CeF2, CrF3, DyF3, EuF3, GaF3, GdF3, FeF3, HoF3, InF3, LaF3, LuF3, MnF3, NdF3, VOF3, PrF3, SbF3, ScF3, SmF3, TbF3, TiF3, TmF3, YF3, YbF3, TIF3, CeF4, GeF4, HfF4, SiF4, SnF4, TiF4, VF4, ZrF4, NbF5, SbF5, TaF5, BiF5, MoF6, ReF6, SF6, and WF6 can be used, but are not limited thereto.
[0269] The manufacturing method of the present invention may further include a step of formulating the reaction mixture obtained after the reaction, if necessary. In the present invention, the formulation method is not particularly limited, but may be performed by passing the mixture through a cartridge containing a polymer adsorbent (copolymer sorboent), and may be performed using, for example, an Oasis WAX Plus short cartridge, but is not limited thereto.
[0270] When using the manufacturing method of the present invention, trifluoroacetic acid can be manufactured in a high yield. In the present invention, the compound represented by the above chemical formula 2 or the copper complex compound of the above chemical formula 1 [ 18 [F] When reacted with fluoride ion, trifluoroacetic acid labeled with fluorine-18 can be produced, and the fluorine-18 labeled trifluoroacetic acid produced in this way can be used to produce additional radiopharmaceuticals.
[0271] According to another embodiment of the present invention, the compound represented by the above chemical formula 2 or the copper complex compound represented by the above chemical formula 1 [ 18 F]fluoride ion or [ 19 [F] It relates to a method for producing trifluoroacetic acid represented by the following chemical formula 14 by reacting with fluoride ion:
[0272] [Chemical Formula 14]
[0273]
[0274] In the above chemical formula 14, X 2 Is 18 F or 19 It's F.
[0275] In the present invention, when the compound of the above chemical formula 2 or the copper complex compound represented by the above chemical formula 1 is reacted with fluoride ion, trifluoroacetic acid of the above chemical formula 14 can be produced.
[0276] In the present invention, the copper complex compound of the above chemical formula 1 can be prepared by reacting the compound of the above chemical formula 2 with the copper complex represented by the above chemical formula 3 as described above.
[0277] In the present invention, the above [ 18 F]fluoride ion or [ 19 [F]Fluoride ion may be added in an amount of 0.2 to 4 equivalents, preferably 0.2 to 2 equivalents, more preferably 0.2 to 1.5 equivalents, and most preferably 1 equivalent to the copper complex compound represented by the above chemical formula 1, but is not limited thereto.
[0278] In the present invention, the compound represented by the above chemical formula 2 or the copper complex compound represented by the above chemical formula 1 and [ 18 F]fluoride ion or [ 19[F] The reaction of fluoride ions is preferably carried out in the presence of a base to increase the reaction efficiency. Here, the base is an alkoxide, such as sodium tert-butoxide; an alkali metal amide, such as sodium amide, lithium diisopropylamide, and an alkali metal bis(trialkylsilyl)amide, such as lithium bis(trimethylsilyl)amide (LiHMDS) or sodium bis(trimethylsilyl)amide (NaHMDS); Tertiary amines (e.g., triethylamine, trimethylamine, 4-(dimethylamino)pyridine (DMAP), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,5-diazabicyclo[5.4.0]undec-5-ene (DBU); alkali or alkaline earth carbonates, bicarbonates or hydroxides (e.g., sodium, magnesium, calcium, barium, potassium carbonate, phosphate, hydroxide and bicarbonate) may be used, and preferably, NaH, LiH, KH, K2CO3, Na2CO3, Tl2CO3, Cs2CO3, K(OtBu), Li(OtBu), Na(OtBu), K(OAr), Na(OAr), triethylamine, or mixtures thereof may be used, but are not limited thereto. In the present invention, the base is a compound represented by the chemical formula 2 or 4. It may be added in an amount of 0.5 to 2 equivalents, preferably 0.75 to 1.5 equivalents, and most preferably 1 equivalent, but is not limited thereto.
[0279] In addition, in the present invention, the reaction of the compound represented by the chemical formula 2 or the copper complex compound represented by the chemical formula 1 and the fluoride ion may be performed at a temperature of 50 to 100°C, preferably 60 to 80°C, more preferably 75°C, but is not limited thereto.
[0280] In addition, in the present invention, the reaction of the compound represented by the above chemical formula 2 or the copper complex compound represented by the above chemical formula 1 and the fluoride ion may be performed for 10 minutes to 6 hours, preferably 10 minutes to 1 hour, more preferably 10 minutes to 30 minutes, but is not limited thereto.
[0281] When using the manufacturing method of the present invention, trifluoroacetic acid can be manufactured in a high yield. In the present invention, the compound represented by the above chemical formula 2 or the copper complex compound of the above chemical formula 1 [ 18 [F] When reacted with fluoride ion, trifluoroacetic acid labeled with fluorine-18 can be produced, and the fluorine-18 labeled trifluoroacetic acid produced in this way can be used to produce additional radiopharmaceuticals.
[0282] According to another embodiment of the present invention, there is provided a method for trifluoroalkylating a ligand using a copper complex compound represented by the above chemical formula 1.
[0283] The trifluoroalkylation method of the present invention may include a step of reacting a ligand with a copper complex compound of the above chemical formula 1 in the presence of a fluoride ion to trifluoroalkylate the ligand.
[0284] In the present invention, the fluoride ion is [ 18 F]fluoride ion or [ 19 F] may be a fluoride ion. [ as a fluoride ion 18 When using F]fluoride ions, the ligand can be labeled with the radioisotope fluorine-18.
[0285] In the present invention, the fluoride ion may be added in an amount of 0.2 to 4 equivalents, preferably 0.2 to 3 equivalents, and more preferably 1 to 3 equivalents, relative to the copper complex compound represented by the chemical formula 1, but is not limited thereto.
[0286] In the present invention, it is preferable that the reaction be performed in the presence of a base to increase the reaction efficiency. Here, the base is an alkoxide, such as sodium tert-butoxide; an alkali metal amide, such as sodium amide, lithium diisopropylamide, and an alkali metal bis(trialkylsilyl)amide, such as lithium bis(trimethylsilyl)amide (LiHMDS) or sodium bis(trimethylsilyl)amide (NaHMDS); Tertiary amines (e.g., triethylamine, trimethylamine, 4-(dimethylamino)pyridine (DMAP), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,5-diazabicyclo[5.4.0]undec-5-ene (DBU); alkali or alkaline earth carbonates, bicarbonates or hydroxides (e.g., sodium, magnesium, calcium, barium, potassium carbonate, phosphate, hydroxide and bicarbonate) may be used, and preferably, NaH, LiH, KH, K2CO3, Na2CO3, Tl2CO3, Cs2CO3, K(OtBu), Li(OtBu), Na(OtBu), K(OAr), Na(OAr), triethylamine, or mixtures thereof may be used, but are not limited thereto. In the present invention, the base is 0.5 to the copper complex compound of the above chemical formula 1. It may be added in an amount of 0.5 to 4 equivalents, preferably 0.5 to 3 equivalents, but is not limited thereto.
[0287] In the present invention, the reaction of the copper complex compound of the above chemical formula 1 and the fluoride ion can be performed in a solvent. Here, the solvent may be any one or more selected from the group consisting of CH3CN, THF (tetrahydrofuran), CH2Cl2, DMF (N,N-dimethylformamide), DMSO (dimethyl sulfoxide), and mixtures thereof, but is not limited thereto.
[0288] In the present invention, even if a copper complex compound of the same chemical formula 1 is used, a trifluoromethyl group or a trifluoroethyl group may be substituted on the ligand depending on the ligand and reaction conditions.
[0289] Trifluoromethylation method
[0290] In the present invention, the ligand to be used to transfer the trifluoromethyl group is an aryl (e.g., C6~C) substituted by at least one substituent selected from the group consisting of a halogen, a boronic acid group (-B(OH)2), and a boronic acid pinacol ester group (-Bpin). 14 As a compound containing an aryl) or heteroaryl (e.g., heteroaryl having 5 to 14 nuclear atoms) structure, it can be included without limitation as long as it is preferably used for the purpose of diagnosing or treating a disease or can be used for imaging.
[0291] In the present invention, the ligand including the halogen-substituted aryl or heteroaryl structure may include a phenyl structure substituted with a fluoro group, a chloro group, a bromo group, an iodine group, a boronic acid group (-B(OH)2), or a boronic acid pinacol ester group (-Bpin), and may be, for example, a compound represented by the following chemical formula 15, but is not limited thereto.
[0292] [Chemical Formula 15]
[0293]
[0294] In the above chemical formula 15,
[0295] X is a halogen, a boronic acid group or a boronic acid pinacol ester group, preferably a halogen,
[0296] Y 1 is N or C(R 8 ) and
[0297] m is an integer from 0 to 4,
[0298] R 7 Silver halogen, nitro, cyano group, C1~C6 alkyl group, C6~C 14 Aryl group, C1~C6 alkoxy group, -C(=O)-R 9 , or -NR 10 C(=O)-R 11 and the above R 7 In this case, they are the same or different from each other,
[0299] R 8 is hydrogen or a C1~C6 alkyl group,
[0300] R 9 is hydrogen, an amine group (-NH2), a C1~C6 alkyl group, or a C1~C6 alkoxy group,
[0301] R 10 and R 11 are each independently hydrogen or a C1~C6 alkyl group.
[0302] Non-limiting examples of the ligand including the halogen-substituted aryl or heteroaryl structure in the present invention may be selected from compounds having the structures below, but are not limited thereto.
[0303]
[0304] In the above chemical formula, X is a halogen, a boronic acid group, or a boronic acid pinacol ester group.
[0305] The trifluoromethylation method of the present invention may include a step of reacting the above-described ligand, the copper complex compound of the above-described chemical formula 1, and a fluoride ion source.
[0306] In the present invention, the halogen, boronic acid group or boronic acid pinacol ester group in the ligand can be substituted with a trifluoromethyl group derived from the compound of chemical formula 1 by a reaction represented by the reaction scheme 1 below.
[0307] [Reaction Formula 1]
[0308]
[0309] In the above reaction scheme 1, each group is as defined above.
[0310] In the present invention, the fluoride ion may be added in an amount of 0.2 to 4 equivalents, preferably 1 to 3 equivalents, to the copper complex compound represented by the chemical formula 1, but is not limited thereto.
[0311] In the present invention, the reaction is preferably carried out in the presence of a base to increase the reaction efficiency. The base may be added in an amount of 0.5 to 4 equivalents, or 0.5 to 3 equivalents, relative to the copper complex compound of the above chemical formula 1. Preferably, during the reaction, [ 18 When using F]fluoride ion, the base may be added in an amount of 0.5 to 1.5 equivalents, or 0.5 to 1 equivalent, to the copper complex compound of the above chemical formula 1. In addition, during the reaction, [ 19 When using F]fluoride ion, the base may be added in an amount of 1 to 4 equivalents, or 1 to 3 equivalents, relative to the copper complex compound of the above chemical formula 1.
[0312] In the present invention, the reaction may be carried out at a temperature of 50 to 200°C, but is not limited thereto. Preferably, during the reaction, fluoride ions are used. 18[F] When using fluoride ion, the reaction can be carried out at a temperature of 100 to 200°C, preferably 125 to 175°C. In addition, during the reaction, [ 19 When using F]fluoride ions, the reaction can be carried out at a temperature of 50 to 200°C, preferably 50 to 150°C or 60 to 80°C.
[0313] In the present invention, the reaction may be carried out for 5 to 120 minutes, but is not limited thereto. Preferably, during the reaction, fluoride ions are used [ 18 [F] When using fluoride ions, the reaction can be carried out for 10 to 30 minutes. In addition, during the reaction, [ 19 When using F]fluoride ions, the reaction can be carried out for 30 to 100 minutes.
[0314] A trifluoromethylation method according to an example of the present invention comprises the above ligand and the copper complex compound of the above chemical formula 1 and [ 19 [F] may include a step of reacting a fluoride ion source. At this time, the above [ 19 [F] The fluoride ion source may be added in an amount of 1 to 3 equivalents relative to the copper complex compound of the above chemical formula 1. In addition, the reaction may be performed at a reaction temperature of 50 to 150° C. for 30 to 100 minutes in the presence of a base in an amount of 1 to 4 equivalents relative to the copper complex compound of the above chemical formula 1, but is not limited thereto.
[0315] A trifluoromethylation method according to an example of the present invention comprises the above ligand and the copper complex compound of the above chemical formula 1 and [ 18[F] A step of reacting a fluoride ion source may be included. At this time, the reaction may be performed at a reaction temperature of 100 to 200° C. for 10 minutes to 30 minutes in the presence of a base in an amount of 0.5 to 1.5 equivalents relative to the copper complex compound of the above chemical formula 1, but is not limited thereto.
[0316] Non-limiting examples of ligands substituted with a trifluoromethyl group according to the method of the present invention may be selected from compounds having the structures below, but are not limited thereto.
[0317]
[0318] In the above chemical formula, X 2 Is 18 F or 19 It's F.
[0319] Trifluoroethylation method
[0320] In the present invention, the ligand to be used to transfer the trifluoroethyl group includes a primary amine group (-NH2) or a secondary amine group (-NRH; here, R may be any substituent) in its structure, and preferably, any ligand that can be used for the purpose of diagnosing or treating a disease or for imaging may be included without limitation.
[0321] Non-limiting examples of the ligand containing the amine group in the present invention include N-methyl-3-phenylpropan-1-amine, N-methylbenzylamine, N,N-diethyl-amine, 1,2,3,4-tetrahydroisoquinoline, 1-methyl-4-piperazine, 4-morpholine, ethyl piperidine-2-carboxylate, piperidin-4-ol, N-(2-(6-methoxy)indolin-3-yl)ethyl)acetamide, indole, It may include, but is not limited to, compounds such as 6-bromoindoline, 4-methylindoline, and N-methylbenzenamine.
[0322] The trifluoroethylation method of the present invention may include a step of reacting a copper complex compound of the above chemical formula 1 with a fluoride ion source to produce trifluoroacetic acid represented by the above chemical formula 14; and a step of reacting the trifluoroacetic acid with the above ligand.
[0323] In the trifluoroethylation method of the present invention, the step of generating the trifluoroacetic acid and the step of reacting the trifluoroacetic acid with the ligand can be performed as two separate steps, but can be performed continuously in one reactor.
[0324] In the present invention, any hydrogen (H) of the amine group in the ligand can be replaced with a trifluoroethyl group derived from trifluoroacetic acid of chemical formula 14 by the reaction represented by the reaction scheme 2 below.
[0325] [Reaction Formula 2]
[0326]
[0327] In the above reaction formula 2,
[0328] means the part where the amine group is connected in the above ligand,
[0329] R 13 is hydrogen or any substituent, such as C1~C6 alkyl group, C6~C 14 It may vary depending on the structure of the ligand, such as an aryl group, and is not particularly limited.
[0330] Also, X 2 Is 18 F or 19 It's F.
[0331] In the present invention, the reaction is preferably performed in the presence of a base to increase reaction efficiency. The base may be added in an amount of 1 to 4 equivalents, or 1 to 3 equivalents, relative to the copper complex compound of Chemical Formula 1, but is not limited thereto.
[0332] In the present invention, the reaction of the copper complex compound represented by the above chemical formula 1 and the fluoride ion can be performed at a temperature of 50 to 100°C, preferably 60 to 80°C, more preferably 75°C, but is not limited thereto.
[0333] In addition, in the present invention, the reaction of the copper complex compound represented by the chemical formula 1 and the fluoride ion may be performed for 10 minutes to 6 hours, preferably 10 minutes to 1 hour, and more preferably 10 minutes to 30 minutes, but is not limited thereto.
[0334] In the present invention, the reaction of the trifluoroacetic acid of the above chemical formula 1 and the ligand containing an amine group can be performed in the presence of a reducing agent. At this time, examples of the reducing agent that can be used include sodium borohydride (NaBH4), sodium cyanoborohydride (NaCNBH3), sodium acetate cyanoborohydride (NaBH3OAc), sodium triacetoxyborohydride, lithium borohydride (LiBH4), lithium aluminum hydride (LiAlH4), (i-Bu2AlH)2, L-selectride, K-selectride, SnCl2, phenylsilane, Et3SiH, and mixtures thereof, and is preferably sodium cyanoborohydride (NaCNBH3), but is not limited thereto. In the present invention, the reducing agent may be added in an amount of 1 to 5 equivalents relative to the ligand, and preferably in an amount of 2 to 5 equivalents, but is not limited thereto.
[0335] In the present invention, the reaction of the trifluoroacetic acid of the above chemical formula 1 and the ligand containing an amine group may be performed at, but is not limited to, 10 to 150°C, preferably 25 to 150°C, more preferably 100 to 150°C, and most preferably 120°C.
[0336] In the present invention, the reaction of the trifluoroacetic acid of the above chemical formula 1 and the ligand containing an amine group may be performed for 5 to 120 minutes, preferably 15 to 60 minutes, and more preferably 20 to 40 minutes, but is not limited thereto.
[0337] Non-limiting examples of ligands substituted with a trifluoroethyl group according to the method of the present invention may be selected from compounds having the structures below, but are not limited thereto.
[0338]
[0339] In the above chemical formula, X 2 Is 18 F or 19 It's F.
[0340] According to the method of the present invention, a trifluoroalkyl group, particularly a trifluoromethyl group or a trifluoroethyl group, can be transferred to the desired ligand, and the fluoride ion [ 18 When using F]fluoride ion, a ligand can be prepared in which a trifluoroalkyl group labeled with fluorine-18 is introduced. In this way, -CF2[ 18 Ligands having the group [F] have excellent stability in the body when administered into the body, and also have excellent lipophilicity and cell penetration.
[0341] Hereinafter, the present invention will be described in more detail through examples. These examples are intended solely to illustrate the present invention more specifically, and it will be apparent to those skilled in the art that the scope of the present invention is not limited by these examples, in accordance with the gist of the present invention.
[0342]
[0343] Example
[0344]
[0345] [Manufacturing Example 1] Synthesis of copper complex compounds
[0346] To synthesize trifluoroacetic acid, a copper complex compound was first synthesized as a reactant. Specifically, 1.2 mmol of NaOtBu was dissolved in 5 mL of THF in a glove box, and 1.0 mmol of CuCl dissolved in 5 mL of THF was added, followed by stirring at room temperature for 90 minutes. The reaction mixture was passed through Celite, and 2.0 mmol of 2,2'-bipyridine (Bpy) dissolved in 10 mL of THF was added to the resulting filtrate, and the mixture was stirred at room temperature for 10 minutes. 1.0 mmol of chlorodifluoroacetic acid dissolved in 3 mL of THF was added dropwise, and the mixture was stirred at room temperature for 10 minutes. The solvent in the reaction mixture was removed in vacuo, and the remaining solid material was washed with diethyl ether, and all remaining solvent was removed in vacuo. A copper complex compound represented by the following chemical formula 31, [(Bpy)2Cu][CF2ClCO2], was synthesized, and the synthesis yield was 70%.
[0347] [Chemical Formula 31]
[0348]
[0349]
[0350] [Manufacturing Example 2] Synthesis of copper complex compounds
[0351] Except that 1,10-phenanthroline (Phen) was used instead of 2,2'-bipyridine as the ligand for preparing a copper complex, the same method as in Manufacturing Example 1 was performed, and [(Phen)2Cu][CF2ClCO2] represented by the following chemical formula 32 was synthesized with a synthetic yield of 73%.
[0352] [Chemical Formula 32]
[0353]
[0354]
[0355] [Manufacturing Example 3] Synthesis of copper complex compounds
[0356] Except that 3,4,7,8-tetramethyl-1,10-phenanthroline was used instead of 2,2'-bipyridine as the ligand for preparing a copper complex, the same method as in Manufacturing Example 1 was performed, and [(TMPhen)2Cu][CF2ClCO2] represented by the following chemical formula 33 was synthesized with a synthetic yield of 68%.
[0357] [Chemical Formula 33]
[0358]
[0359]
[0360] [Experimental Example 1] Comparison of Synthetic Yields of Trifluoroacetic Acid (TFA) According to Reactants
[0361] Chlorodifluoroacetic acid or the copper complex compound (0.02 mmol) synthesized in the above Preparation Examples 1 to 3, Cs2CO3 (0.02 mmol) as a base, and CsF (0.02 mmol) as a fluoride ion source were dissolved in DMF and stirred at 75°C for 1 hour to synthesize trifluoroacetic acid.
[0362] However, in order to compare the synthesis yield of trifluoroacetic acid according to the type of reactant used in the above reaction or the use or non-use of base, after the reaction is completed, it is sufficiently cooled to room temperature. 19 The amount of trifluoroacetic acid produced was measured using F-NMR, and the results are shown in Table 1 below.
[0363] Distinctive reagent base synthesis yield (%) Comparative example 1CF2ClCOOHNoneNR Example 1CF2ClCOOHCs2CO31.6 ± 0.4 Example 2 Manufacturing example 1: [(BPy)2Cu][CF2ClCO2]Cs2CO36.6 ± 0.7 Example 3 Manufacturing example 2: [(Phen)2Cu][CF2ClCO2]Cs2CO37.5 ± 1.1 Example 4 Manufacturing example 3: [(TMPhen)2Cu][CF2ClCO2]Cs2CO310.3 ± 1.2
[0364] As shown in Table 1 above, when only chlorodifluoroacetic acid was used, trifluoroacetic acid was not produced, but when a base (Cs2CO3) was added, trifluoroacetic acid was synthesized. In addition, when the copper complex compounds synthesized in Preparation Examples 1 to 3 as reactants were reacted with a base (Cs2CO3), trifluoroacetic acid was synthesized, and among the copper complex compounds, it was seen that the synthesis yield of trifluoroacetic acid was the highest when [(TMPhen)2Cu][CF2ClCO2] synthesized in Preparation Example 3 was used.
[0365]
[0366] [Experimental Example 2] Comparison of the synthetic yield of trifluoroacetic acid (TFA) according to reaction time and fluorine addition equivalent amount.
[0367] Before labeling fluorine-18, an experiment was conducted to determine the degree of trifluoroacetic acid synthesis according to the fluorine equivalent and time. Since fluorine-18 is only a trace amount compared to fluorine-19, the amount of trifluoroacetic acid produced was compared according to the fluorine-19 equivalent and reaction time. [(TMPhen)2Cu][CF2ClCO2] (0.02 mmol), the copper complex compound that showed the highest synthesis rate in Experimental Example 1, and Cs2CO3 (0.02 mmol) were placed in a reaction vessel, and CsF as a fluorine source was dissolved in DMF in three different volumes (0.004, 0.02, 0.04 mmol) and stirred at 75°C for 1 hour. After sufficiently cooling the reaction vessel to room temperature at each reaction time (15, 30, 45, 60 minutes), 19 The amount of trifluoroacetic acid produced was measured using F-NMR, and the results are shown in Figure 1 and Table 2 below.
[0368] CsF(eq)TFA Synthesis Yield (%) 15 min 30 min 45 min 60 Lost Example 5 1 1 1 3 5 2 0 1 0 Example 6 2 7 1 5 8 1 Example 7 0.2 3 16 13 4
[0369] As shown in Table 2 and Fig. 1, regardless of the amount of CsF added, trifluoroacetic acid was produced in the largest amount 30 minutes after the start of the reaction and the amount produced tended to decrease thereafter. In addition, it was observed that trifluoroacetic acid was produced even when a small amount of 0.2 equivalents of CsF was added as a fluorine source, and it was confirmed that the amount of trifluoroacetic acid produced was the greatest when 1 equivalent was added.
[0370]
[0371] [Experimental Example 3] Evaluation of N-trifluoroethylation efficiency of ligands according to reducing agent and reaction temperature.
[0372] The following experiment was conducted to determine the optimal reaction conditions for N-trifluoroethylation by in-situ reaction using trifluoroacetic acid synthesized in the previous experiment.
[0373] Copper complex compounds [(TMPhen)2Cu][CF2ClCO2] (3 eq), Cs2CO3 (3 eq), and CsF (3 eq) were placed in a reaction vessel, dissolved in DMF, and stirred at 75°C for 30 minutes. After cooling the reaction mixture to room temperature, the model compound (1 eq) of the following chemical formula 34 containing a secondary amine group and a reducing agent were added in the types and amounts shown in Table 3 below, and stirred for another 30 minutes at room temperature or 125°C. After sufficiently cooling the reaction mixture to room temperature, 19 The yield of the final product was measured using F-NMR, and the results are shown in Table 3 below.
[0374] [Chemical Formula 34]
[0375]
[0376] Reducing agentReducing agent EquivalentReaction temperature(℃)Production yield(%)Example 8NaBH42 Equivalent12026.5 ± 4.9Example 9NaBH45 Equivalent12011.5 ± 3.0Example 10 a. NaCNBH32 equivalent 258.7 ± 1.2 Example 11 a. NaCNBH32 Equivalent 1203.8 ± 0.7Example 12NaCNBH31 Equivalent 12020.1 ± 2.6Example 13NaCNBH32 Equivalent 12042.9 ± 1.7Example 14NaCNBH35 Equivalent 12015.3 ± 2.3 a. Add HCl (0.1 eq)
[0377] As shown in Table 3 above, when NaBH4 was used as a reducing agent in equivalent amounts, the trifluoroethylation efficiency was approximately 26.5%, but as the equivalent amount increased, the efficiency tended to slightly decrease. On the other hand, when NaCNBH3 was used as a reducing agent, it was observed that the trifluoroethylation efficiency increased up to 40%. However, when the reaction was performed under acidic conditions as in Examples 10 and 11 or at room temperature, it was confirmed that the trifluoroethylation efficiency actually decreased.
[0378]
[0379] [Experimental Example 4] Synthesis of Fluorine-18-labeled Trifluoroacetic Acid
[0380] 18O(p, n) from cyclotron 18 Through the F reaction [ 18 After obtaining F]fluoride, [ 18 F]Fluoride K 2,2,2 By heating and separating from QMA Sep-pak using acetonitrile solution containing dissolved K2CO3, K 18 F / K 2,2,2 Got K 18 F / K 2,2,2In a reaction vessel containing [(TMPhen)2Cu][CF2ClCO2] copper complex (10 mg) and Cs2CO3 (9.5 mg) obtained in the above Preparation Example 3 were added, dissolved in DMF (0.3 mL), and a stirring bar was added, followed by stirring at 70°C for 20 minutes. After the reaction time was over, the reaction vessel was sufficiently cooled to room temperature, and then HPLC was performed using an ion exchange column under the conditions of 5 mM H2SO4 100%, 0.5 mL / min, 210 nm to confirm the mixed product of the reaction.
[0381] In the HPLC results by RI detector of Fig. 2, a peak was observed at approximately 8.2 minutes. In the HPLC results by UV detector, a peak was observed at approximately 8.1 minutes. 19 As the F-TFA peak was observed, the peak at 8.2 minutes confirmed in the RI HPLC results through comparison of retention times 18 It was confirmed that this was due to the F-TFA (RI detector). In the same way, it was confirmed that fluorine-18 remained unreacted after 14.8 minutes.
[0382]
[0383] [Experimental Example 5] Isolation and formulation of fluorine-18 labeled trifluoroacetic acid from a reaction mixture
[0384] 1. From the reaction mixture 18 Separation of F-TFA
[0385] From Experimental Example 4, copper complex compounds and [ 18 [F] Fluorine-18 labeled trifluoroacetic acid ( 18 Although F-TFA) was produced, it was confirmed that unreacted fluorine-18 was mixed in. Therefore, from the reaction mixture 18To separate only F-TFA, a Sep-Pak alumina N plus cartridge (Sep-Pak Alumina N plus, trade name, manufactured by Waters Co.) was used. Preconditioning was performed by sequentially passing 5 mL of ethanol and 20 mL of water through the Sep-Pak cartridge. The reaction mixture obtained in Experimental Example 4 was diluted by adding 20 mL of water and then passed through the Sep-Pak cartridge. Afterwards, 10 mL of water was passed through the Sep-Pak cartridge to wash it. Unreacted fluorine-18 was removed from the reaction mixture. 18 To confirm that only F-TFA was separated, the radioactivity of the reaction mixture before washing, the Sep-pak cartridge after washing, and the filtrate (waste) that passed through the Sep-pak cartridge were measured using a dose calibrator, and are shown in Table 4 below. In addition, HPLC analysis was performed on the filtrate that passed through the Sep-pak cartridge, and the results are shown in Fig. 3.
[0386] Reaction mixture activity (μCi)Sep-pak activity (μCi)Waste activity (μCi)Alumina N plus416.8362.446.2
[0387] As shown in Table 4 above, the radioactivity in the Sep-pak where the reaction mixture was adsorbed was 362.4 μCi, and the radioactivity in the elution filtrate that passed through the Sep-pak was 46.2 μCi. In addition, referring to Figure 3, which is the result of HPLC analysis on the elution filtrate, at approximately 8.0 minutes 18 The F-TFA peak was observed, but the fluorine-18 peak could not be confirmed. From this, when the reaction mixture was passed through a Sep-pak cartridge, fluorine-18 was adsorbed to the Sep-pak and remained. 18 It was found that F-TFA was eluted and separated.
[0388] 2. 18Formulation of F-TFA
[0389] Previously separated 18 Since F-TFA is diluted in 20 mL of water, a formulation process is required to convert it into the required solution and appropriate amount to use it for trifluoroethylation of the ligand. For the formulation, an ion exchange Sep-pak is used. 18 After adsorbing F-TFA onto Sep-pak, an experiment was conducted to determine whether it could be eluted with the required solution. 5 mL of ethanol and 20 mL of water were sequentially passed through an Oasis (registered trademark) WAX Plas (trade name, Nihon Waters KK) cartridge to perform pre-conditioning. Afterwards, the previously separated 18 The elution filtrate containing F-TFA and 20 mL of water was passed through a WAX Sep-pak. The amount of radioactivity adsorbed on the Sep-pak cartridge was confirmed, and the radioactivity of the resulting filtrate was checked after elution with saline solution (1 mL), and the results are shown in Table 5 below. In addition, HPLC analysis was performed on the elution filtrate, and the results are shown in Figure 4.
[0390] Process radioactivity (μCi) First elution filtrate of reaction product 46.2 WAX Sep-pak adsorption 36.9 Sikyeongsu Second elution filtrate 22.1
[0391] As shown in Table 5 above, the first elution filtrate of the reaction product contains 18 It was confirmed that most of the F-TFA was adsorbed on the WAX Sep-pak cartridge and eluted with saline solution. As shown in Figure 4, which is the HPLC analysis result for the secondary saline solution filtrate, it was found that at approximately 8.0 minutes 18 F-TFA peak was observed. This shows that the synthesized product according to the present invention 18It was found that F-TFA can be separated and purified using a Sep-pak cartridge containing alumina, and can be formulated into a desired formulation using a WAX cartridge.
[0392]
[0393] [Experimental Example 6] Evaluation of N-trifluoroethylation of ligands
[0394] Obtained in the above experimental example 4 18 After the reaction mixture containing F-TFA was cooled to room temperature, a ligand containing a primary amine group (1 eq) and NaCNBH3 (5 eq) were additionally added, and the mixture was stirred at 125°C for an additional 30 minutes. After the reaction mixture was sufficiently cooled to room temperature, the product was isolated by HPLC, and the yield was measured by radioactivity. As a result, a radiochemical yield of approximately 17% and a specific radioactivity of 2.12 GBq / μmol were obtained. The obtained product was co-injected into HPLC with a ligand containing fluorine-19 prepared in advance, and the compound was identified by comparing the retention times. However, HPLC was performed using an Xterra C18 column and was analyzed for 20 minutes at a wavelength of 254 nm with a flow rate of 3 mL / min under the conditions of 0.1% formic acid / CH3CN: 0.1% formic acid / DW = 35:65.
[0395] As shown in Fig. 5, the synthesized according to the present invention 18 Using F-TFA to ligands containing primary amine groups [ 18 It was found that F]N-trifluoroethylation had occurred.
[0396] Through the above experiments, it was shown that the method of the present invention can synthesize fluorine-18 labeled trifluoroacetic acid with high yield and ease, and furthermore, it can be separated and formulated. In addition, when using the fluorine-18 labeled trifluoroacetic acid synthesized in the present invention, it is possible to [ 18 F] enables trifluoroethylation, and thus [ 18 The ligand with the F]trifluoroethyl group introduced has the advantage of excellent stability when administered into the body and also excellent cell penetration ability.
[0397]
[0398] [Experimental Example 7] Evaluation of trifluoromethylation efficiency of ligands according to reaction conditions
[0399] The following experiment was conducted to determine the optimal reaction conditions for performing N-trifluoromethylation using the [(TMPhen)2Cu][CF2ClCO2] copper complex compound synthesized in the preceding Manufacturing Example 3.
[0400] 1. Selection of optimal reaction conditions for N-trifluoromethylation depending on the fluoride ion source.
[0401] The model compound 1-iodo-4-nitrobenzene (1 eq) was mixed with copper complex compounds [(TMPhen)2Cu][CF2ClCO2] (n eq) and Cs2CO3 (n eq), and CsF (3 eq) or K as a fluoride ion source. 18 F / K 2.2.2 After placing it in a reaction vessel, it was dissolved in DMF. The reaction was carried out at 75 ℃ or 150 ℃ as a reaction temperature. When CsF was used as a fluoride ion source, the reaction was carried out with stirring for 1 hour, and when K was used as a source 18 F / K 2,2,2 When used, the reaction was carried out with stirring for 20 minutes. After the reaction mixture was sufficiently cooled to room temperature, 19The yield of the final product was measured using F-NMR and the results are shown in Table 6. When radioisotopes were used, the radiochemical yield was measured using Radio-TLC and the results are shown in Table 7.
[0402] Copper complex compoundFluoride ion sourceBase (eq)Reaction temperature (℃)Yield (%)Example 152 eqCsFCs2CO3(3 eq)7581.5 ± 0.7Example 161.5 eqCsFCs2CO3(1 eq)7585.0 ± 1.4Example 171 eqCsFCs2CO3(1 eq)7557.5 ± 0.7Example 181 eqCsFCs2CO3(3 eq)15023.5 ± 4.9
[0403] Copper complex compound Fluoride ion source Base (eq) Reaction temperature (℃) Radiochemical yield (%) Example 192 eq K 18 F / K 2,2,2 Cs2CO3(3 eq)754.8 ± 3.6 Example 201.5 eqK 18 F / K 2,2,2 Cs2CO3(1 eq)752.2 ±1.9 Example 221 eqK 18 F / K 2,2,2 Cs2CO3(3 eq)15050.3 ± 2.3
[0404] As shown in Table 6 above, the reaction using CsF, i.e. fluorine-19, as a fluoride ion source had the best reaction yield at 75°C, and the reaction yield was highest when 1.5 equivalents of copper complex compound and 1 equivalent of base were used. However, it was confirmed that the reaction yield decreased when the reaction temperature was increased to 150°C. As shown in Table 7 above, when K was used as a fluoride ion source, 18 F / K 2,2,2That is, in the reaction using fluorine-18, it was confirmed that when the reaction temperature was set to 75 ℃, the reaction yield and radiochemical yield increased significantly when the reaction temperature was raised to 150 ℃. Therefore, in the reaction using fluorine-18, the conditions of using 1 equivalent of copper complex compound, using 3 equivalents of base, and setting the reaction temperature to 150 ℃ were selected as the optimal reaction conditions.
[0405] 2. Check for fluorine-18 labeling
[0406] In order to confirm whether the compound obtained under the optimal reaction conditions using fluorine-18 was actually labeled with fluorine-18, HPLC analysis was performed. 19 The retention times of the compounds introduced with F were compared. However, the HPLC test conditions were as follows. The analysis results are shown in Figure 6.
[0407] System: Agilent Separation Products System with gamma-ray detectors and UV (254 nm)
[0408] Semi-preparative Column: Xterra, RP-18 C18; 4.6 x 250 mm, 10 μm
[0409] Dissolution solution: 50% CH3CN / H2O
[0410] Flow rate: 3 mL / min
[0411] As shown in Figure 6, through the above reaction, a fluorine-18 labeled trifluoromethyl group (-CF2) is formed at the iodine position of 1-iodo-4-nitrobenzene. 18 It was confirmed that F) was substituted.
[0412]
[0413] [Experimental Example 8] Evaluation of trifluoromethylation efficiency in various ligands
[0414] Copper complex compounds with ligands having various functional groups [ 18 F]fluoride ion or [ 19 The following experiment was performed to determine whether trifluoromethylation was possible by reacting F]fluoride ions.
[0415] 1. Evaluation of trifluoromethylation yield by ligand
[0416] A ligand (1 eq) having various functional groups substituted and containing an iodine-substituted aryl group or heteroaryl group as shown in Table 7 below, a copper complex compound [(TMPhen)2Cu][CF2ClCO2] (1.5 eq) and Cs2CO3 (1 eq), and CsF (3 eq) as a fluoride ion source were placed in a reaction vessel, dissolved in DMF, and stirred at 75°C for 1 hour. Afterwards, the reaction vessel was cooled to room temperature. 19 The yield of the final product was measured using F-NMR, and the results are shown in Table 8 below.
[0417] Example 23: Yield of reaction product (%) Example 24 Example 25 of 78 Example 26 Example 27 of 68 Example 28 Example 29 Example 28: 30 Example 31 Example 30: 32 Example 33 Example 26: 34 Example 27: 35 Example 31: 36 Flutamide 47
[0418] As shown in Table 8, trifluoromethylation was observed in various ligands containing iodine-substituted aryl or heteroaryl structures. In particular, trifluoromethylation was observed in flutamide (Example 36), which is used as a prostate cancer treatment.
[0419] 2. Evaluation of ligand-specific fluorine-18-labeled trifluoromethylation yields
[0420] The ligand (1 eq) shown in Table 7 above was added to the copper complex compounds [(TMPhen)2Cu][CF2ClCO2] (1 eq) and Cs2CO3 (3 eq), and K as a fluoride ion source. 18 F / K2,2,2 was placed in a reaction vessel, dissolved in DMF, and stirred at 150°C for 20 minutes. Afterwards, the reaction vessel was cooled to room temperature. 18 The yield of the final product was measured using F-NMR and the results are shown in Table 9 below.
[0421] Example 37: Yield of reaction product (%) Example 38 Example 39 Example 46 Example 16 41 Example 21: 42 Example 31: 43 Example 25: 44 Example 45 of 69 Example 32: 46 Example 15: 47 Example 36: 48 Example 24: 49 Example 21: 50 Flutamide 41
[0422] As shown in Table 9 above, it was confirmed that fluorine-18 labeled trifluoromethylation occurred in various ligands containing iodine-substituted aryl or heteroaryl structures, and it was also observed that fluorine-18 labeled trifluoromethylation occurred in high yield in flutamide (Example 50), which is used as a prostate cancer treatment agent.
[0423] While specific aspects of the present invention have been described in detail above, it should be apparent to those skilled in the art that these specific descriptions are merely preferred implementation examples and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.
[0424] The present invention relates to a building block that can be utilized for trifluoroalkylation in the production of a radioactive fluorine-18 labeled radiopharmaceutical for medical diagnosis, a method for producing the same, and a method for trifluoroalkylating a ligand using the same.
Claims
1. A trifluoroalkylation method comprising the step of reacting a copper complex compound of the following chemical formula 1 with a ligand in the presence of a fluoride ion to trifluoroalkylate the ligand: [Chemical Formula 1] In the above chemical formula 1, Cy1 to Cy4 are each independently a heteroaryl or heterocycloalkenyl ring having 4 to 8 atoms, Cy5 and Cy6 are each independently a cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl or heterocycloalkenyl ring having 0 to 8 atoms, R 1 Inland R 6 are each independently hydrogen, halogen, nitro, C1~C6 alkyl group or C6~C 14 As an aryl group, it is a mono-substituent or a multi-substituent that is the same or different, X 1 is a halogen excluding the fluoro group.
2. In paragraph 1, The above fluoride ion is [ 18 F]fluoride ion or [ 19 F]Fluoride ion, trifluoroalkylation method.
3. In paragraph 1, A trifluoroalkylation method, wherein the fluoride ion is added in an amount of 0.2 to 4 equivalents to the copper complex compound.
4. In paragraph 1, A trifluoroalkylation method wherein the above reaction is carried out in the presence of a base.
5. In paragraph 4, A trifluoroalkylation method wherein the base is NaH, LiH, KH, K2CO3, Na2CO3, Tl2CO3, Cs2CO3, K(OtBu), Li(OtBu), Na(OtBu), K(OAr), Na(OAr), triethylamine, or a mixture thereof.
6. In paragraph 4, A trifluoroalkylation method, wherein the base is added in an amount of 0.5 to 4 equivalents to the copper complex compound of the above chemical formula 1.
7. In paragraph 1, The above ligand comprises an aryl or heteroaryl structure substituted with a halogen, a boronic acid group or a boronic acid pinacol ester group, A trifluoroalkylation method, wherein the above step is a method in which a halogen, boronic acid group or boronic acid pinacol ester group in the ligand is replaced with a trifluoromethyl group.
8. In paragraph 7, The above ligand is a compound represented by the following chemical formula 15, trifluoroalkylation method: [Chemical Formula 15] In the above chemical formula 15, X is a halogen, a boronic acid group or a boronic acid pinacol ester group, Y 1 is N or C(R 8 ) and m is an integer from 0 to 4, R 7 Silver halogen, nitro, cyano group, C1~C6 alkyl group, C6~C 14 Aryl group, C1~C6 alkoxy group, -C(=O)-R 9 , or -NR 10 C(=O)-R 11 and the above R 7 In this case, they are the same or different from each other, R 8 is hydrogen or a C1~C6 alkyl group, R 9 is hydrogen, an amine group (-NH2), a C1~C6 alkyl group, or a C1~C6 alkoxy group, R 10 and R 11 are each independently hydrogen or a C1~C6 alkyl group.
9. In paragraph 7, A trifluoroalkylation method wherein the ligand is selected from compounds having the following structures: In the above chemical formula, X is a halogen, a boronic acid group, or a boronic acid pinacol ester group.
10. In paragraph 7, The above fluoride ion is added in an amount of 0.2 to 4 equivalents to the copper complex compound, A trifluoroalkylation method, wherein the above reaction is carried out at a temperature of 50 to 200°C for 5 to 120 minutes.
11. In paragraph 7, A trifluoroalkylation method, wherein the above reaction is carried out in the presence of 0.5 to 4 equivalents of a base with respect to the copper complex compound.
12. In paragraph 10, The above fluoride ion is [ 18 F] fluoride ion, and the reaction is carried out at 100 to 200°C for 10 to 30 minutes, a trifluoroalkylation method.
13. In paragraph 10, The above fluoride ion is [ 19 F] fluoride ion, and the reaction is carried out at 60 to 80° C. for 30 to 100 minutes, a trifluoroalkylation method.
14. In paragraph 1, The above ligand comprises a primary amine group or a secondary amine group, The above step is a trifluoroalkylation method in which hydrogen (H) of an amine group in the ligand is replaced with a trifluoroethyl group.
15. In paragraph 14, The ligands are N-methyl-3-phenylpropan-1-amine, N-methylbenzylamine, N,N-diethyl-amine, 1,2,3,4-tetrahydroisoquinoline, 1-methyl-4-piperazine, 4-morpholine, ethyl piperidine-2-carboxylate, piperidin-4-ol, N-(2-(6-methoxy)indolin-3-yl)ethyl)acetamide, indole, A trifluoroalkylation method, wherein the trifluoroalkylation method comprises a compound selected from the group consisting of 6-bromoindoline, 4-methylindoline, and N-methylbenzenamine.
16. In paragraph 14, The above step is a trifluoroalkylation method comprising: a step of reacting a copper complex compound of the above chemical formula 1 with a fluoride ion source to produce trifluoroacetic acid represented by the following chemical formula 14; and a step of reacting the trifluoroacetic acid with the ligand. [Chemical Formula 14] In the above chemical formula 14, X 2 Is 18 F or 19 It's F.
17. In paragraph 14, A trifluoroalkylation method, wherein the reaction of the copper complex compound and the fluoride ion is performed in the presence of a base added in an amount of 1 to 4 equivalents with respect to the copper complex compound of the chemical formula 1.
18. In paragraph 14, A trifluoroalkylation method, wherein the reaction of the trifluoroacetic acid and the ligand is performed in the presence of a reducing agent added in an amount of 1 to 5 equivalents relative to the ligand.
19. In paragraph 14, A trifluoroalkylation method, wherein the reaction of the trifluoroacetic acid and the ligand is performed at 10 to 150°C for 5 to 120 minutes.
20. A ligand comprising the method of any one of claims 1 to 19, [ 18 [F]Method for producing a radiopharmaceutical substituted with a fluoroalkyl group.
21. A building block composition for trifluoroalkylation comprising a copper complex compound represented by the following chemical formula 1: [Chemical Formula 1] In the above chemical formula 1, Cy1 to Cy4 are each independently a heteroaryl or heterocycloalkenyl ring having 4 to 8 atoms, Cy5 and Cy6 are each independently a cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl or heterocycloalkenyl ring having 0 to 8 atoms, R 1 Inland R 6 are each independently hydrogen, halogen, nitro, C1~C6 alkyl group or C6~C 14 As an aryl group, it is a mono-substituent or a multi-substituent that is the same or different, X 1 is a halogen excluding the fluoro group.
22. In paragraph 21, The above copper complex compound is a composition represented by the following chemical formula 6 or 7: [Chemical Formula 6] [Chemical Formula 7] In the above chemical formulas 6 and 7, R 1 Inland R 6 Wow X 1 is as defined in Article 21.
23. A copper complex compound represented by the following chemical formula 1 or a compound represented by the following chemical formula 2 [ 18 F]fluoride ion or [ 19 [F] A method for producing trifluoroacetic acid represented by the following chemical formula 14 by reacting with fluoride ion: [Chemical Formula 1] [Chemical Formula 2] [Chemical Formula 14] In the above chemical formulas 1, 2 and 14, Cy1 to Cy4 are each independently a heteroaryl or heterocycloalkenyl ring having 4 to 8 atoms, Cy5 and Cy6 are each independently a cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl or heterocycloalkenyl ring having 0 to 8 atoms, R 1 Inland R 6 are each independently hydrogen, halogen, nitro, C1~C6 alkyl group or C6~C 14 As an aryl group, it is a mono-substituent or a multi-substituent that is the same or different, X 1 is a halogen excluding fluoro group, X 2 Is 18 F or 19 It's F.
Citation Information
Patent Citations
Copper difluorocarbene reagent, and preparation method and application thereof
CN104910195A
